A plot of ACTH levels in response to insulin provocation is shown below.

**Reviewer's comments:** Since ACTH is often interpreted in the setting of cortisol levels, please see my comments after the cortisol section below.

**Cortisol:** Although the responsiveness of cortisol levels to insulin provocation was similar between at baseline and Day 7 (i.e. $C_{\text{max}}$ was not statistically different), the mean AUC at endpoint was significantly less that that at baseline ($p=0.016$). This difference in AUC was attributed to reduced steady state levels of plasma cortisol after 7 days of treatment with nebivolol.

| Changes in Plasma Cortisol Levels (µg/dL) During the Insulin Tests |
|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| **Time (minutes)**       | **Baseline (Day 0)**     | **Endpoint (Day 7)**     | **Change from baseline to endpoint p-value** |
|                          | **Mean (SEM)**           | **95% CI of mean**       | **Mean (SEM)**           | **95% CI of mean**       |                                |
| -30                      | 13.6 (1.5)               | 10.4, 16.9               | 9.7 (1.1)                | 7.3, 12.0                |                                |
| -15                      | 11.8 (1.5)               | 8.5, 15.0                | 8.5 (1.1)                | 6.1, 10.9                |                                |
| 0                        | 11.4 (1.7)               | 7.8, 15.0                | 7.8 (1.2)                | 5.2, 10.5                |                                |
| +30                      | 12.8 (1.2)               | 10.2, 15.4               | 10.4 (1.0)               | 8.2, 12.6                |                                |
| +60                      | 21.4 (0.8)               | 19.7, 23.1               | 20.8 (0.9)               | 18.8, 22.8               |                                |
| +90                      | 21.9 (0.9)               | 19.9, 23.9               | 21.0 (0.9)               | 19.1, 22.9               |                                |
| +120                     | 20.7 (1.0)               | 18.5, 22.9               | 19.6 (1.1)               | 17.3, 22.0               |                                |
| **AUC**                  | 2175 (84)                | 1990, 2361               | 1994 (93)                | 1789, 2199               | 0.016                          |
| **Cmax**                 | 23.1 (0.9)               | 21.2, 24.9               | 21.9 (0.9)               | 20.0, 23.9               | 0.519                          |

A plot of plasma cortisol levels in response to insulin provocation is shown below.
Reviewer's comments: The ACTH findings complement the cortisol findings. The basal, unstimulated ACTH levels were slightly lower post- vs. pre-treatment with nebivolol. This likely explains the lower basal cortisol levels post-nebivolol treatment. Additionally, the urinary cortisol findings (see below) parallel the serum findings – there was a statistically significant reduction in 24-hour urinary cortisol levels post-nebivolol.

The post-nebivolol ACTH peak during the insulin test was also lower than that pre-nebivolol. This did not appear to affect the maximal cortisol response to hypoglycemia but the concern is that if there is a continued reduction in ambient ACTH levels with prolonged nebivolol use and/or higher nebivolol doses, adrenal atrophy and insufficiency could occur.

A longer duration study is required with doses up to 10 mg daily to adequately assess the effects of nebivolol on the HPA axis. Tests such as the low-dose ACTH test or the insulin tolerance test should be in addition to the high-dose ACTH test because the latter lacks sensitivity for detecting partial insufficiency states.

Growth Hormone: The response of growth hormone to insulin was numerically greater after treatment with nebivolol than at baseline, however, the AUC and C_{max} differences were not statistically significant.
### Changes in Serum Growth Hormone Levels (mU/L) During the Insulin Tests

<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Baseline (Day 0)</th>
<th>Endpoint (Day 7)</th>
<th>Change from baseline to endpoint p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SEM)</td>
<td>95% CI of mean</td>
<td>Mean (SEM)</td>
</tr>
<tr>
<td>-30</td>
<td>5.5 (1.7)</td>
<td>1.8, 9.2</td>
<td>8.0 (2.7)</td>
</tr>
<tr>
<td>-15</td>
<td>3.9 (1.1)</td>
<td>1.5, 6.4</td>
<td>6.1 (2.4)</td>
</tr>
<tr>
<td>0</td>
<td>4.2 (1.8)</td>
<td>0.2, 8.2</td>
<td>5.4 (1.9)</td>
</tr>
<tr>
<td>+30</td>
<td>12.8 (5.2)</td>
<td>1.3, 24.2</td>
<td>10.3 (3.0)</td>
</tr>
<tr>
<td>+60</td>
<td>87.1 (12.6)</td>
<td>59.3, 114.9</td>
<td>105.3 (17.6)</td>
</tr>
<tr>
<td>+90</td>
<td>90.2 (13.7)</td>
<td>60.2, 120.2</td>
<td>107.0 (19.3)</td>
</tr>
<tr>
<td>+120</td>
<td>56.9 (9.8)</td>
<td>35.4, 78.4</td>
<td>68.8 (10.4)</td>
</tr>
</tbody>
</table>

AUC: 6480 (926) 4442, 8518 7648 (1159) 509, 10198 0.57
Cmax: 98.4 (13.0) 69.9, 126.9 113.9 (19.3) 71.4, 156.3 0.79

**Reviewer's comments:** This finding is of uncertain significance.

A plot of serum growth hormone levels in response to insulin provocation is shown below.

![Graph showing changes in serum growth hormone levels](image)

**Prolactin**: The response of prolactin to insulin was numerically smaller after treatment with nebivolol than at baseline, however, the AUC and C_{max} differences were not statistically significant.
<table>
<thead>
<tr>
<th>Time (minutes)</th>
<th>Baseline (Day 0)</th>
<th>Endpoint (Day 7)</th>
<th>Change from baseline to endpoint p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Mean (SEM)</td>
<td>95% CI of mean</td>
<td>Mean (SEM)</td>
</tr>
<tr>
<td>-30</td>
<td>306.3 (23.2)</td>
<td>255.3, 357.2</td>
<td>260.3 (18.7)</td>
</tr>
<tr>
<td>-15</td>
<td>255.3 (15.7)</td>
<td>220.6, 289.9</td>
<td>230.0 (17.5)</td>
</tr>
<tr>
<td>0</td>
<td>264.6 (14.4)</td>
<td>232.9, 296.2</td>
<td>226.4 (15.7)</td>
</tr>
<tr>
<td>+30</td>
<td>366.8 (49.4)</td>
<td>258.2, 475.5</td>
<td>389.3 (63.9)</td>
</tr>
<tr>
<td>+40</td>
<td>1666.1 (430.0)</td>
<td>719.7, 2612.5</td>
<td>1311.7 (274.4)</td>
</tr>
<tr>
<td>+60</td>
<td>1832.9 (400.9)</td>
<td>950.6, 2715.2</td>
<td>1601.0 (314.0)</td>
</tr>
<tr>
<td>+90</td>
<td>1411.4 (319.5)</td>
<td>708.2, 2114.7</td>
<td>1276.8 (255.9)</td>
</tr>
<tr>
<td>+120</td>
<td>993.0 (235.1)</td>
<td>475.5, 1510.5</td>
<td>962.1 (185.1)</td>
</tr>
</tbody>
</table>

**AUC**: 138229 (28975) | 74455, 202003 | 122010 (22478) | 72537, 171483 | 0.62

**Cmax**: 2004.6 (454.6) | 1004.1, 3005.1 | 1619.8 (314.0) | 928.7, 2310.8 | 0.62

**Reviewer's comments**: This finding is of uncertain clinical significance.

**24-Hour Urinary Hormone Levels**: Urinary cortisol levels (unadjusted and creatinine-adjusted) were significantly lower after nebivolol treatment that at baseline.
### Changes in 24-Hour Urinary Hormone Levels

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Mean (SEM)</th>
<th>Mean (SEM)</th>
<th>Change (Days 0 to 7)</th>
<th>95% CI for the mean change from baseline</th>
<th>Change from baseline p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline (Day 0)</td>
<td>Endpoint (Day 7)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urine volume (mL)</td>
<td>1467.5 (145.4)</td>
<td>1389.2 (171.0)</td>
<td>-78.3 (121.3)</td>
<td>-345.3, 188.6</td>
<td>0.60</td>
</tr>
<tr>
<td>Total creatinine (g)</td>
<td>1.4 (0.2)</td>
<td>1.6 (0.2)</td>
<td>0.2 (0.1)</td>
<td>0.0, 0.4</td>
<td>0.064</td>
</tr>
<tr>
<td>Aldosterone, µg</td>
<td>10.0 (2.4)</td>
<td>10.2 (2.1)</td>
<td>0.2 (2.2)</td>
<td>-4.6, 5.0</td>
<td>0.91</td>
</tr>
<tr>
<td>Cortisol, µg</td>
<td>52.9 (8.3)</td>
<td>38.1 (3.9)</td>
<td>-14.8 (6.2)</td>
<td>-28.5, -1.1</td>
<td>0.034</td>
</tr>
<tr>
<td>Aldosterone/creatinine (µg/g)</td>
<td>7.3 (2.0)</td>
<td>7.4 (1.5)</td>
<td>0.1 (1.8)</td>
<td>-4.0, 4.1</td>
<td>0.91</td>
</tr>
<tr>
<td>Cortisol/creatinine (µg/g)</td>
<td>41.0 (6.1)</td>
<td>26.6 (3.2)</td>
<td>-14.3 (4.2)</td>
<td>-23.6, -5.1</td>
<td>0.002</td>
</tr>
</tbody>
</table>

**Reviewer's comments:** Although cortisol levels likely remained within the normal range (based on the 95% confidence intervals), this finding is concerning and suggests reduced exposure to cortisol over a 24-hour time period. Further investigation needs to assess higher nebivolol doses and longer duration of therapy.

It is surprising that no clinical adverse events were reported during the trial, especially since symptomatic hypoglycemia would be anticipated during the insulin tests.

**Sponsor's Conclusions:** Nebivolol 5 mg daily for 7 days did not significantly alter the basal, nonstimulated levels of testosterone, LH, ACTH, aldosterone, renin, growth hormone or prolactin. There were statistically significant decreases in mean basal, non-stimulated plasma cortisol and 24-hour urinary cortisol levels. The observed reduction in the 2-hour AUC for plasma cortisol seen during the insulin provocation test was associated with the lower steady state levels of plasma cortisol and did not reflect reduced responsiveness to the hypoglycemic stimulus. Therefore, the Sponsor claims the HPA axis remained intact with treatment with nebivolol.

**Reviewer's comments:** The cortisol findings are worrisome. The reduced basal levels of cortisol in association with reduced ambient ACTH levels and lower 24-hour urinary free cortisol excretion post-nebivolol occurred with the 5 mg dose given for only 7 days. For chronic control of hypertension, subjects are likely to be exposed to this medication long-term and at higher doses. Therefore, the potential for nebivolol to cause adrenal insufficiency with long-term use at higher doses should be evaluated.
The Effect of Nebivolol on the State of the Pituitary-Gonadal System and on Lipid Peroxidation Processes in Young and Middle-Aged Men with Arterial Hypertension

Investigator: M.D. Rakhmatullaeva (Tashkent, Uzbekistan)
Submitted for Publication: April 2002
Sponsor and Conflicts of Interest: Not listed, but the briefing packet claims the Sponsor did not support this study.

Reviewer's comments: The original article is in Russian – the Sponsor has provided a translated version

Objectives: To study the effect of nebivolol on (1) lipid peroxidation, (2) the antioxidant system, and (3) the pituitary-gonadal system in men with arterial hypertension.

Study Design: Non-randomized study assessing the endocrine effects of nebivolol in 32 men with hypertension. The results from the nebivolol group were compared to hormonal parameters that were measured in a control group that was not given nebivolol. This control group consisted of 10 normotensive (systolic blood pressure <130 mmHg; diastolic blood pressure <90 mmHg) "essentially" healthy men, each of whom underwent a single measurement of FSH, LH, and testosterone.

The ages of the entire group ranged from 30-65 years (mean 45.5±3.4 years).

Reviewer's comments: The author comments that the healthy men were "of the same age" as the hypertensive subjects - ages for subjects in each group are not explicitly stated.

For the hypertensive group, preceding anti-hypertensive medications were discontinued 1-2 weeks prior to starting nebivolol. These subjects started nebivolol 5 mg daily, but the dose was increased to 10 mg daily at 4 weeks if there was an inadequate blood pressure response. The total duration of therapy was 12 weeks.

Reviewer's comments: This study is of appropriate duration, but the control group was not well-defined in the manuscript – did the control group have any co-morbidities or were members in the control group taking any concomitant medications? A randomized, controlled study would have been a much more powerful design that would have produced more robust results. Also, the manuscript does not include the number of subjects who had an increase in nebivolol dose to 10 mg daily.

Primary Endpoints: Not explicitly stated
Secondary Endpoints: Not explicitly stated
Inclusion Criteria Included:
1. Hypertension Group: Young and middle-aged men (30-65 years old) with "mild" or "moderate" hypertension
2. Control Group: Essentially healthy men "of the same age [as the hypertensive patients]" with systolic blood pressure <130 mmHg and diastolic blood pressure <90 mmHg

Exclusion Criteria Included:
1. Prior myocardial infarction or stroke
2. Symptomatic or malignant arterial hypertension
3. Chronic renal or liver disease
4. Diabetes

Assessments Included:
Fasting, morning blood samples for testosterone, FSH, and LH (using RIA kits from Immunotech, Czech Republic and from the Scientific Research Institute of Endocrinology and of Regional Medicine of the Ministry of Health of the Republic of Uzbekistan).

Reviewer's comments: Hormone samples appear to have been drawn at the correct time of day. The manuscript does not describe the statistical tests used.

Results:

| Changes in Blood Pressure Over Time with Nebivolol Therapy (n=32) |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|
| Blood Pressure                  | Baseline       | 2 Weeks        | 4 Weeks        | 8 Weeks        | 12 Weeks       |
| Systolic, mmHg                  | 152.4±2.4      | 142.3±3.1      | 140.5±2.6      | 136.7±2.1      | 132.2±2.7*     |
| Diastolic, mmHg                 | 104.1±1.5      | 94.2±1.7       | 90.1±1.9       | 86.1±1.2       | 82.2±1.3**     |

*The author reports p<0.05 compared with baseline
*The author reports p<0.01 compared with baseline

Normalization of diastolic blood pressure occurred in 28 (87.5%) of the hypertensive subjects. The remaining 4 subjects had a partial response (diastolic blood pressure change >10%).

| Pituitary-Gonadal System in Patients with Hypertension as Compared with Control |
|---------------------------------|----------------|----------------|----------------|----------------|----------------|
| Hormone                         | Control Group (n=10) | Hypertensive Patients (n=32) | Baseline | 4 Weeks | 12 Weeks |
| FSH, mIU/mL                     | 6.2±0.18       | 7.9±0.19*      | 7.5±0.16†     | 7.0±0.13§      |
| LH, mIU/mL                      | 6.4±0.12       | 8.4±0.19*      | 7.6±0.18‡     | 6.9±0.15§      |
| Testosterone, ng/mL             | 4.8±0.11       | 1.8±0.05*      | 2.3±0.15§     | 3.6±0.13§      |

*The author reports p<0.05 compared with control group
†The author reports p<0.05 compared with the baseline values
The author reports p<0.01 compared with the baseline values
§The author reports p<0.001 compared with the baseline values

**Reviewer's comments:** In what proportion of subjects were baseline and post-treatment testosterone levels frankly low and in what proportion of subjects with abnormally low levels of testosterone was there normalization of levels with nebivolol?

The author claims that LH and FSH levels were statistically higher and testosterone levels were statistically lower in the hypertensive subjects at baseline compared with the corresponding hormones measured in the normotensive group. In the hypertensive group, the LH and FSH levels were progressively lowered and the testosterone levels were progressively raised from 4 to 12 weeks of treatment with nebivolol.

**Reviewer's comments:** Without information about the statistical tests used, I cannot determine whether the data were analyzed appropriately (e.g. was a paired test used?) However, at face value, there does appear to be an increase in testosterone and a lowering of LH and FSH with nebivolol therapy. I am reluctant to compare the results with the control group given the trial design and poor characterization of the control group.

The author stated that “when the dose of the drug is increased by 2.5-5 mg according to indications, the extent of its influence on PGS [pituitary-gonadal system] hormones increased somewhat.” No data are presented in the manuscript to support this claim.

In the Discussion section, the author mentioned that the effects of nebivolol on vasodilation (via nitric oxide modulation) in the vessels of the sex glands and corpora cavernosa in men may explain the elaboration of testosterone by the glands and improvement in erectile function.

**Reviewer's comments:** The manuscript does not contain information about hypogonadal symptoms (e.g. erectile dysfunction) pre- and post-treatment with nebivolol (even if it did, the unblinded, uncontrolled design would limit interpretation).

**Sponsor's Conclusions:** Although results from this uncontrolled published study should be interpreted with caution, the findings suggest that nebivolol 5 to 10 mg/day, administered over 12 weeks in hypertensive men, was associated with changes in mean pituitary-gonadal hormone levels, resulting in levels similar to those in normotensive control subjects.

**Reviewer's comments:** Conclusions are limited given the uncontrolled trial design and missing descriptions of the statistical tests employed. Also, the positive 4-week findings in this study contrast with the null 4-week testosterone results in NEB-CAN-09. Therefore, I would consider the results from this study as “hypothesis-generating” and recommend confirmation in a well-designed trial. In general, beta-blockers, are associated with erectile dysfunction and have been
shown to decrease testosterone levels in normal volunteers and hypertensive patients (the Sponsor has listed the applicable studies on page 42 of the “BetaBlockerComp” PDF file in the electronic submission).

Metabolic and Antihypertensive Effects of Nebivolol and Atenolol in Normometabolic Patients with Mild-to-Moderate Hypertension

Authors: Yves Pesant (Hotel-Dieu Hospital, St-Jerome), Julien Marc-Aurele (Sacré-Coeur Hospital, Montreal), Pierre Bielmann (Centre Hospitalier de l-Universite Lava, Quebec, Canada), Peter Alaupovic (Oklahoma Medical Research Foundation, Oklahoma City, OK), Pierre Cartier (Sacré-Coeur Hospital, Montreal), Daniel Bichet (Sacré-Coeur Hospital, Montreal), Gaeten Thibault (Clinical Research Institute of Montreal, Montreal, Canada), Paul Lupien (Centre Hospitalier de l-Universite Lava, Quebec, Canada)


Conflicts of Interest: Supported by an educational grant from Janssen-Ortho, Inc.

Primary Objectives: To study the effect of nebivolol in comparison to atenolol on lipids and on carbohydrate metabolism (hemoglobin A1C, glucose, insulin, C-peptide).

Secondary Objectives: To assess safety, tolerability, the hormone profile and hypertensive efficacy of nebivolol and atenolol in normo-metabolic patients with mild-to-moderate essential hypertension.

Study Design: Four-week single-blind, placebo washout phase followed by a 12-week double-blind treatment phase with either nebivolol (5 mg) or atenolol (50 mg) once daily.

Reviewer’s comments: This study is of appropriate duration but, again, used only one-half the maximum recommended dose (10 mg/day) in humans for which the Sponsor is seeking approval.

Inclusion Criteria Included:
1. Mild-to-moderate essential hypertension (WHO grade I-II)
2. Normometabolic
   a. Fasting total cholesterol <240 mg/dL
   b. Fasting triglycerides <220 mg/dL
   c. Fasting blood glucose <116 mg/dL
   d. Hemoglobin A1C <6%

Reviewer’s comments: Ages of participants were not mentioned. It is not clear why the authors chose 116 mg/dL for the glucose cut-off value. In 1999, impaired fasting glucose was defined as a blood glucose concentration 110-125 mg/dL (the lower limit of impaired fasting glucose has subsequently been reduced to 100 mg/dL). Even by 1999 standards, some of the subjects included in this study may
have had impaired fasting glucose. However, if subjects with this mild abnormality were included (i.e. fasting blood glucose 110-116 mg/dL) I doubt the results of the hormonal tests would be significantly affected.

Exclusion Criteria Included:
1. Diabetes mellitus or fasting blood glucose >116 mg/dL, or hemoglobin A1C >6%
2. Asthma or chronic obstructive pulmonary disease or heart failure
3. Weight >30% over ideal body weight
4. Serum creatinine >2.0 mg/dL
5. Conditions with possible clinical effects on lipids (e.g. liver disease, alcohol use)
6. Pregnant or nursing women and those of childbearing potential.
7. Cardiac arrhythmias
8. Significant liver disease (transaminitis >2.5x upper limit of normal)
9. Concomitant medications affecting blood pressure (e.g. NSAIDs) or lipids (e.g. glucocorticoids)

Assessments Included:
1. Lipid parameters
2. Two-hour, 75g oral glucose tolerance test at the end of the washout period (i.e. at randomization) and at the end of the 12-week treatment period
3. Hormonal profile – drawn at randomization and at the end of the treatment period
   a. Plasma renin activity
   b. Aldosterone
   c. Prolactin
   d. Cortisone
   e. ACTH
   f. Serum thyrotropin (TSH)

Statistical Plan: Intent-to-treat analyses. Lipids and hormonal variables were assessed with ANOVA and ANCOVA (covariate = last determination during baseline). Dunnett’s procedure was used for multiple comparisons versus baseline. Bartlett’s test was used to assess the significance of differences between variables. All analyses used a two-sided alpha of 0.05. No power calculations were presented.
Results:

<table>
<thead>
<tr>
<th>Baseline Data</th>
<th>Nebivolol (n=21)</th>
<th>Atenolol (n=16)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, yr</td>
<td>53.8±9.1</td>
<td>55.6±8.4</td>
<td>NS</td>
</tr>
<tr>
<td>Weight, kg</td>
<td>75.5±14.4</td>
<td>75.4±12.8</td>
<td>NS</td>
</tr>
<tr>
<td>Male/female</td>
<td>9/12</td>
<td>8/8</td>
<td>NS</td>
</tr>
<tr>
<td>Cigarette non-smoker/smoker</td>
<td>15/5</td>
<td>12/4</td>
<td>NS</td>
</tr>
<tr>
<td>Alcohol, yes/no</td>
<td>7/14</td>
<td>11/5</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Total cholesterol, mmol/L</td>
<td>5.00±0.74</td>
<td>4.58±0.82</td>
<td>NS</td>
</tr>
<tr>
<td>Total triglycerides, mmol/L</td>
<td>1.49±0.39</td>
<td>1.47±0.18</td>
<td>NS</td>
</tr>
<tr>
<td>Systolic blood pressure, mmHg</td>
<td>150±17</td>
<td>160±20</td>
<td>NS</td>
</tr>
<tr>
<td>Diastolic blood pressure, mmHg</td>
<td>98±7</td>
<td>99±5</td>
<td>NS</td>
</tr>
<tr>
<td>Sitting heart rate (beat/min)</td>
<td>72±11</td>
<td>73±11</td>
<td>NS</td>
</tr>
</tbody>
</table>

Plus-minus values are mean±SD; NS, non-significant

Patient compliance was evaluated by tablet counting. During the 12-week active treatment period, 14 doses (<1% of all nebivolol doses) were missed by the nebivolol group and 7 doses (<1% of all atenolol doses) were missed by the atenolol group. Both drugs reduced blood pressure and heart rate to a similar extent. No drug-related adverse events were reported.

**Oral Glucose Tolerance Test:** The changes in the oral glucose tolerance test parameters observed at the end of 12 weeks between nebivolol and atenolol were not statistically significant.

**Reviewer's comments:** According to the Table, treatment with nebivolol or atenolol did not significantly alter basal glucose, insulin, or C-peptide levels nor did these medications alter the response of these variables to the oral glucose tolerance test. However, according to the text, atenolol caused a statistically significant increase in basal serum glucose from baseline to the end of treatment (mean increase from 92 to 100 mg/dL). Some beta-blockers, including atenolol have been shown to cause impaired glucose tolerance and worsening insulin sensitivity (Lithell 1991).
Oral Glucose Tolerance Results Before and After 3 Months of Nebivolol or Atenolol Treatment

<table>
<thead>
<tr>
<th></th>
<th>Baseline (n=30)</th>
<th>Nebivolol (n=17)</th>
<th>Atenolol (n=13)</th>
<th>P within group</th>
<th>Atenolol treatment (n=12)</th>
<th>P within group</th>
<th>P between group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Basal glucose (mmol/L)</td>
<td>5.22±0.45</td>
<td>5.09±0.72</td>
<td>5.29±0.51</td>
<td>NS</td>
<td>5.57±0.86</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Basal glucose (mg/dL)</td>
<td>94±8</td>
<td>92±13</td>
<td>95±9</td>
<td>NS</td>
<td>100±15</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Basal insulin (mU/L)</td>
<td>54.3±26.7</td>
<td>62.0±43.0</td>
<td>61.4±32.9</td>
<td>NS</td>
<td>56.6±32.2</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Basal C-peptide (µg/L)</td>
<td>1.94±0.62</td>
<td>2.23±1.33</td>
<td>2.02±0.94</td>
<td>NS</td>
<td>2.28±1.39</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>AUC Glucose 0-2h</td>
<td>1034±201</td>
<td>929±200</td>
<td>1043±225</td>
<td>NS</td>
<td>964±217</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>(h x mmol/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC Insulin 0-2h</td>
<td>57012±26173</td>
<td>53815±33067</td>
<td>61867±41212</td>
<td>NS</td>
<td>56109±42061</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>(h x mU/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC C-peptide 0-2h</td>
<td>943±280</td>
<td>955±362</td>
<td>894±352</td>
<td>NS</td>
<td>974±413</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>(h x µg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Plus-minus values are mean±SD; NS, non-significant

ACTH:

Treatment with either nebivolol or atenolol significantly reduced ACTH levels from baseline (for nebivolol: 3.0±1.6 to 2.2±2.0 pg/mL; p=0.032. For atenolol: 5.0±3.6 to 2.4±2.7 pg/mL; p=0.038). The decreases in ACTH levels were not statistically different between the two treatment groups.

Reviewer’s comments: ACTH levels were also reduced post-nebivolol in the insulin-induced hypoglycemia study.

Aldosterone:

Aldosterone levels increased with nebivolol and declined with atenolol. Neither of these changes were statistically significant. However, there was a statistically significant difference in aldosterone levels between the nebivolol and atenolol groups (p=0.03).

Reviewer’s comments: These random aldosterone levels are uninterpretable, especially without knowledge of the subject’s sodium balance and positioning.

Cortisol:

Cortisol levels declined in both treatment groups, but only the change in the atenolol group was statistically significant (p=0.039). Cortisol levels were not statistically different between treatment groups.
## Endocrine Profile Before and After 3 Months of Nebivolol or Atenolol Treatment

<table>
<thead>
<tr>
<th></th>
<th>Baseline (n=30)</th>
<th>Nebivolol treatment (n=17)</th>
<th>P within group</th>
<th>Atenolol treatment (n=12)</th>
<th>P within group</th>
<th>P between group</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTH (ng/L or pg/mL)</td>
<td>3.0±1.6 (17)</td>
<td>2.2±2.0 (14)</td>
<td>0.032</td>
<td>2.4±2.7 (10)</td>
<td>0.038</td>
<td>NS</td>
</tr>
<tr>
<td>Aldosterone (ng/dL)</td>
<td>3.0±2.3 (17)</td>
<td>3.8±3.6 (14)</td>
<td>NS</td>
<td>2.1±0.9 (8)</td>
<td>NS</td>
<td>0.03</td>
</tr>
<tr>
<td>Cortisol (nmol/L)</td>
<td>14.2±5.3 (17)</td>
<td>12.1±5.9 (16)</td>
<td>NS</td>
<td>13.6±7 (12)</td>
<td>0.039</td>
<td>NS</td>
</tr>
<tr>
<td>PRA (ng/mL/h)</td>
<td>0.998±0.882 (15)</td>
<td>1.181±1.401 (13)</td>
<td>NS</td>
<td>1.187±0.937 (8)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Prolactin (µg/L or ng/mL)</td>
<td>8.1±3.4 (17)</td>
<td>8.5±5.8 (16)</td>
<td>NS</td>
<td>8.86±79.6 (12)</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>TSH (mU/L)</td>
<td>1.69±0.91 (17)</td>
<td>1.61±0.91 (16)</td>
<td>NS</td>
<td>1.58±1.24 (12)</td>
<td>NS</td>
<td>NS</td>
</tr>
</tbody>
</table>

Plus-minus values are mean±SD; NS, non-significant

**Reviewer's comments:** In the nebivolol group, cortisol levels were slightly lower post-treatment when compared to baseline but this did not reach statistical significance. There appeared to be a greater reduction in basal cortisol levels in the insulin study than in the current study. Differences between the studies include (1) healthy volunteers (insulin study) vs. hypertensive patients (current study) and (2) 1-week treatment with nebivolol (insulin study) vs. 4-week treatment (current study). Additionally, the current study did not do provocative testing of the HPA axis or 24-hour urine collections for cortisol.

**Sponsor's Conclusions:** There were no significant differences between treatments with respect to mean values for ACTH, cortisol, or plasma renin activity at endpoint. For mean aldosterone values, there was a non-significant increase in the nebivolol group and a non-significant decrease in the atenolol group, resulting in a significant difference between treatments for mean values for aldosterone at endpoint.

**Reviewer's comments:** Nebivolol significantly lowered ACTH levels but this only had a non-significant lowering effect on basal cortisol levels. The renin and aldosterone levels are uninterpretable based on the same issues raised throughout this review.

The hormone data from the five clinical nebivolol trials in this review are summarized by the Sponsor in the Table below. Methodological issues limit this consultant’s ability to agree with some of these conclusions.
### Table 13: Hormonal effects of nebivolol in humans obtained from five clinical studies

<table>
<thead>
<tr>
<th>Hormone</th>
<th>NEB-CAN-09*</th>
<th>NEB-BEL-52</th>
<th>NEB-BEL-55</th>
<th>Pesant</th>
<th>Rakhamatulhaeva</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Basal</td>
<td>Stim**</td>
<td>Basal</td>
<td>Stim**</td>
<td></td>
</tr>
<tr>
<td>Testosterone</td>
<td>↔</td>
<td>↔</td>
<td>NA</td>
<td>↔</td>
<td>NA</td>
</tr>
<tr>
<td>LH</td>
<td>↔</td>
<td>↔</td>
<td>NA</td>
<td>↔</td>
<td>NA</td>
</tr>
<tr>
<td>FSH</td>
<td>↔</td>
<td></td>
<td>↔</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Estradiol</td>
<td>↔</td>
<td></td>
<td>↔</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Prolactin</td>
<td>-</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td></td>
</tr>
<tr>
<td>GH</td>
<td>-</td>
<td>↔</td>
<td>↔</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Progesterone</td>
<td>↔</td>
<td></td>
<td>↔</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Renin</td>
<td>↓</td>
<td>↔</td>
<td>NA</td>
<td>-</td>
<td>↔</td>
</tr>
<tr>
<td>Cortisol</td>
<td>↔</td>
<td>↓</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
</tr>
<tr>
<td>Aldosterone</td>
<td>↔</td>
<td>↔</td>
<td>NA</td>
<td>↓</td>
<td>↔</td>
</tr>
<tr>
<td>ACTH</td>
<td>↔</td>
<td>↔</td>
<td>↔</td>
<td>-</td>
<td>↔</td>
</tr>
</tbody>
</table>

* Data presented for dl-nebivolol
** Effect on response evoked by insulin-induced hypoglycemia (NEB-BEL-52) or exogenous ACTH administration (NEB-BEL-55)

↔ = no change, ↑ = increased, ↓ = decreased, - = not assessed, LH = luteinizing hormone, FSH = follicle stimulating hormone, GH = growth hormone, NA = not applicable, ACTH = adrenocorticotropic hormone, ANF-C = atrial natriuretic factor-C terminal, ANF-N = atrial natriuretic factor-N terminal, TSH = thyroid stimulating hormone

**A Comparison of the Effects of Beta-Adrenoreceptor Antagonists on Endocrine Organs, Reproductive Toxicity, and Physiological Endpoints: Human Data**

The Table below, compiled by the Sponsor, demonstrates the reported effects of various beta-blockers on hormones in humans. All references are provided in the Sponsor’s electronic submission.
<table>
<thead>
<tr>
<th>Hormone</th>
<th>Effect on basal serum/plasma levels</th>
<th>Beta-blockers showing this effect</th>
<th>Effect on stimulated serum/plasma levels</th>
<th>Beta-blockers showing this effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testosterone</td>
<td>↑</td>
<td>Propranolol</td>
<td>↑</td>
<td>Propranolol</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Acebutolol, Metoprolol, Osprenolol, Propranolol</td>
<td>↓</td>
<td>Metoprolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Acebutolol, Metoprolol, Osprenolol, Propranolol</td>
<td>↔</td>
<td>Metoprolol</td>
</tr>
<tr>
<td>LH</td>
<td>↑</td>
<td>Anapracline</td>
<td>↑</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Atenolol, Nadolol, Propranolol</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Acebutolol, Propranolol, Tolamanol</td>
<td>↔</td>
<td>Metoprolol, Propranolol</td>
</tr>
<tr>
<td>FSH</td>
<td>↑</td>
<td>Anapracline</td>
<td>↑</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Acebutolol, Atenolol, Nadolol, Propranolol</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Propranolol</td>
<td>↔</td>
<td>Metoprolol, Propranolol</td>
</tr>
<tr>
<td>Estradiol</td>
<td>↑</td>
<td>Anapracline, Nadolol</td>
<td>↑</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Atenolol</td>
<td>↓</td>
<td>NA</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Atenolol</td>
<td>↔</td>
<td>Metoprolol</td>
</tr>
<tr>
<td>Prolactin</td>
<td>↑</td>
<td>Anapracline, Labetalol, Medroxalol, Nadolol, Tolamanol</td>
<td>↑</td>
<td>Metoprolol, Propranolol</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Acebutolol, Pindolol, Propranolol</td>
<td>↓</td>
<td>Pindolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Atenolol, Bopindolol, Labetalol, Medroxalol, Metoprolol, Osprenolol, Pindolol, Propranolol, Tolamanol</td>
<td>↔</td>
<td>Atenolol, Propranolol</td>
</tr>
<tr>
<td>GH</td>
<td>↑</td>
<td>Propranolol, osprenolol</td>
<td>↑</td>
<td>Alprenolol, Atenolol, Betaxalol, Metoprolol, Pindolol, Propranolol</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>NA</td>
<td>↓</td>
<td>Bupranolol, Metoprolol, Pindolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Acebutolol, Atenolol, Labetalol, Medroxalol, Metoprolol, Osprenolol, Pindolol, Propranolol, Tolamanol, Timolol</td>
<td>↔</td>
<td>Atenolol, Metoprolol, Propranolol, Timolol</td>
</tr>
</tbody>
</table>

Appears This Way On Original
<table>
<thead>
<tr>
<th>Hormone</th>
<th>Effect on basal serum/plasma levels</th>
<th>Beta-blockers showing this effect *</th>
<th>Effect on stimulated serum/plasma levels</th>
<th>Beta-blockers showing this effect *</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cortisol</td>
<td>↑</td>
<td>Atenolol, Pindolol, Propranolol</td>
<td>↑</td>
<td>Metoprolol, Pindolol, Propranolol, Timolol</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Atenolol, Propranolol</td>
<td>↓</td>
<td>Pindolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Acebutolol, Atenolol, Bopindolol, Dilevalol, Metoprolol, Penbutolol, Pindolol, Propranolol</td>
<td>↔</td>
<td>Acebutolol, Alpenrolol, Betaxolol, Metoprolol, Pindolol, Propranolol</td>
</tr>
<tr>
<td>ACTH</td>
<td>↑</td>
<td>Propranolol</td>
<td>↑</td>
<td>Metoprolol, Pindolol, Propranolol</td>
</tr>
<tr>
<td></td>
<td>↓</td>
<td>Atenolol, Propranolol</td>
<td>↓</td>
<td>Pindolol, Propranolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Propranolol</td>
<td>↔</td>
<td>Betaxolol</td>
</tr>
<tr>
<td>Aldosterone</td>
<td>↓</td>
<td>Amosulol, Atenolol, Bisoprolol, Dilevalol, Penbutolol, Propranolol</td>
<td>↓</td>
<td>Propranolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Oxpresol, Pindolol, Propranolol</td>
<td>↔</td>
<td>Propranolol</td>
</tr>
<tr>
<td>Plasma renin</td>
<td>↓</td>
<td>Amosulol, Bisoprolol, Dilevalol, Oxpresol, Penbutolol, Propranolol</td>
<td>↓</td>
<td>Metoprolol, Propranolol, Timolol</td>
</tr>
<tr>
<td></td>
<td>↔</td>
<td>Atenolol, Dilevalol, Metoprolol, Pindolol, Propranolol</td>
<td>↔</td>
<td>Propranolol</td>
</tr>
</tbody>
</table>

* A given beta-blocker may have shown different results in clinical studies of various designs and therefore may be listed more than once.

↑ = increase; ↓ = decrease; ↔ no change. ACTH = adrenocorticotropic hormone, LH = luteinizing hormone, FSH = follicle-stimulating hormone, GH = growth hormone

As is readily apparent from the Table above, inconsistent results on the hormonal system have been described for different beta-blockers and sometimes even for the same beta-blocker. Therefore, the inconsistent results obtained for nebivolol across the 5 clinical studies is in line with inconsistencies obtained for other beta-blockers. However, it is important to realize that there are significant limitations in most of the nebivolol trials, which have likely contributed substantially to this variability — limitations that most assuredly exist in the other beta-blocker studies.

Other than fetal growth restriction, little has been reported regarding adverse effects of beta-blocker treatment during pregnancy.
Response to Questions from Cardio-Renal

1. For the clinical studies (NEB-CAN-09, NEB-BEL-52, NEB-BEL-55, Pesant, and Rakhmatullaeva):
   a. Do the above studies rule out a possible endocrine effect of nebivolol? If not, why not?

**DMEP Response:** In general, the 5 clinical studies do not rule out a possible endocrine effect of nebivolol, mostly because of methodological issues, which are summarized for the individual studies below. All but one of these studies tested only 5 mg/day of nebivolol, which is one-half the maximum recommended dose (10 mg/day) in humans for which the Sponsor is seeking approval. The one study (Rakhmatullaeva; n=32) that included titration to 10 mg/day of nebivolol did not specify the proportion of participants exposed to this higher dose. For all 5 studies, random aldosterone and renin levels provide limited data about the integrity of the renin-angiotensin-aldosterone system and are dependent on body position and dietary sodium intake, which were not specified in any of the studies. None of the studies evaluated free sex-hormone (e.g. free testosterone and free estradiol) levels.

**CAN-09:**

The protocol does not describe the methodological details regarding determination of the hormone levels. For example, no information was provided as to the types of hormonal assays used. The timing of the hormone collections was not specified (cortisol, ACTH and testosterone levels are highest in the mornings – were these hormones consistently drawn in the mornings for all subjects?). Estradiol and progesterone levels vary widely in healthy premenopausal women depending on the timing of the draw with regard to the menstrual cycle – the study did not take this into account.

**BEL-52:**

This was one of the better designed nebivolol hormonal studies, but it only provides data from short-term (7-day) nebivolol 5 mg/day exposure. Basal ACTH levels were slightly lower post- vs. pre-treatment with nebivolol, which likely explains the lower basal cortisol levels post-nebivolol treatment. Additionally, there was a statistically significant reduction in 24-hour urinary cortisol levels post-nebivolol, which parallels the serum findings. The ACTH peak during the insulin test performed post-nebivolol was also lower than that pre-nebivolol. This did not appear to affect the maximal cortisol response to hypoglycemia but the concern is that if there is a continued reduction in ambient ACTH levels with prolonged nebivolol use and/or higher nebivolol doses, adrenal atrophy and insufficiency could occur.
BEL-55:
The high-dose ACTH test, which was used to assess the integrity of the hypothalamic-pituitary-adrenal (HPA) axis has several limitations. First, this dose causes ACTH levels to increase ~1,000 times higher than what is observed in maximally stressed individuals, thereby potentially causing a falsely normal cortisol response by an adrenal gland that is in fact partially impaired. Second, this test will be falsely negative in patients with newly-acquired (i.e. <1 month) secondary adrenal insufficiency (e.g. ACTH deficiency) because adrenal atrophy only occurs in the setting of chronic ACTH deficiency. Since the BEL-55 study was only 7 days in duration and used the high-dose ACTH test, we are not reassured by the negative HPA results for nebivolol.

Rakhmatullaeva:
This study (translated from Russian) provided exposure to doses of nebivolol up to 10 mg/day for 3 months. However, this was a non-randomized study and the control group was not well-defined in the manuscript. Furthermore, the author did not include a statistical methods section so there is no way of knowing which statistical tests were used to compare the hormone values.

Pesan:
Nebivolol significantly reduced ACTH levels in this study (as it did in NEB-52), but there were no statistically significant differences in pre- and post-nebivolol basal cortisol levels. However, basal cortisol levels provide limited information about the integrity of the HPA axis and no provocative testing (e.g. insulin-induced hypoglycemia or ACTH stimulation testing) was performed.

b. As some of these studies were performed 10 years ago, do you agree with the methods used in these studies to obtain hormone measurements? Could more accurate results of hormone measurements be made with the technology we have today?

DMEP Response: Not all the studies have provided a description of the assays used to measure hormone levels. For those studies that have provided details, the analytic methods appear appropriate even by today’s standards. Issues related to blood collection (e.g. timing of day, timing during menstrual cycle, dietary sodium intake for aldosterone, etc.) appear to be more problematic in these studies.

c. In these studies, was the duration of nebivolol therapy adequate for detecting any possible endocrine changes? If not, what would be the recommended duration of therapy prior to hormonal testing?
DMEP Response: Please also see response to 1a above. The two studies that tested the integrity of the HPA axis with provocative testing (BEL-52 and BEL-55) only exposed subjects to nebivolol for 7 days. In the insulin study (NEB-52), the reduced basal levels of cortisol in association with reduced ambient ACTH levels and lower 24-hour urinary free cortisol excretion post-nebivolol occurred with the 5 mg dose given for only 7 days. Patients are likely to be exposed to this medication long-term and possibly at higher doses. Therefore, the potential for nebivolol to cause adrenal insufficiency with long-term use at higher doses should be evaluated. Since significant ACTH deficiency on the order of 1 month is needed to develop some degree of adrenal atrophy, the normal ACTH stimulation test after 7 days of nebivolol exposure (BEL-55) also does not rule out potential long-term adrenal insufficiency with this agent. Even though the CAN-09 study provided a 4-week exposure to nebivolol, the methodological flaws (please see response to 1a) significantly impair interpretation of most of the hormonal values from that study. The Rakhmatullaeva and Pesant studies each provided 3 month exposure to nebivolol. However, the Rakhmatullaeva study only evaluated men and only evaluated gonadotropins (LH, FSH) and testosterone levels. The Pesant study was of appropriate duration but did not include provocative testing or measurement of gonadotropins or sex-hormones. Finally, virtually all subjects in these studies were exposed to only a 5 mg daily dose of nebivolol.

Therefore, we would recommend a randomized, well-designed study of ~3 months duration testing up to the 10 mg recommended maximum dose of nebivolol in both men and women (see response to 1e for further details regarding this study).

d. Do we agree with the Sponsor’s interpretation of the study results regarding the hormone effects?

DMEP Response: No. We have addressed each of the Sponsor’s claims one-by-one below. Additional details are included in our responses to other questions.

Sponsor’s Claim: Nebivolol had no effects on the HPA axis in humans based on testing using insulin-induced hypoglycemia and ACTH-stimulated glucocorticoid and mineralocorticoid production.

DMEP Response: The insulin-induced hypoglycemia study (BEL-52) did show changes in the HPA axis, including slightly lower basal ACTH levels post- vs. pre-treatment with nebivolol, lower basal cortisol levels post-nebivolol treatment, a statistically significant reduction in 24-hour urinary cortisol levels post-nebivolol, and a lower post-nebivolol ACTH peak during the insulin test. The ACTH-stimulation study (BEL-55) used high-dose ACTH and will be falsely negative in patients with newly-acquired (i.e. <1 month) secondary adrenal insufficiency (e.g. ACTH deficiency) because adrenal atrophy only occurs in the setting of chronic ACTH deficiency.
Sponsor's Claim: Nebivolol did not affect basal, non-stimulated cortisol levels in three clinical studies (NEB-CAN-09, NEB-BEL-55, and the Pesant study). Another study (BEN-BEL-52) showed a statistically significant decrease in basal, non-stimulated cortisol levels and urinary cortisol levels in subjects given nebivolol for 7 days, but the Sponsor questions the relevance of this study because the maximal cortisol response to acute ACTH stimulation was unchanged and the 4-week NEB-CAN-09 and 12-week Pesant studies did not show an effect on basal, non-stimulated cortisol levels.

DMEP Response: Basal cortisol levels provide only limited information about the integrity of the HPA axis. Provocative testing is needed to fully assess this axis. Unchanged results to acute ACTH stimulation (BEL-55) are not reassuring (please see responses to 1a).

Sponsor's Claim: Nebivolol did not have consistent effects on aldosterone and renin levels across clinical studies. The Sponsor attributed the statistically significant decrease in basal, non-stimulated plasma renin levels in NEB-CAN-09 to the known class effect of beta-blockers on the renin-angiotensin-aldosterone system.

DMEP Response: The aldosterone and renin results from all the studies are uninterpretable because the investigators did not control for dietary sodium intake and body position. These confounders probably contributed to the inconsistent results. Additionally, even correctly obtained random aldosterone and renin measurements offer limited information about the integrity of the renin-angiotensin-aldosterone system, unless there are large changes in results.

Sponsor's Claim: Nebivolol did not affect basal, non-stimulated LH, FSH, estradiol, progesterone, or testosterone in men and women in the 4-week NEB-CAN-09 study.

DMEP Response: The LH, FSH, estradiol, and progesterone results are uninterpretable in women because these were not timed appropriately with regard to the menstrual cycle in the pre-menopausal group. Furthermore, progesterone levels were lowered in men, but for unclear reasons no statistical tests were applied to that data. The null results with regard to LH, FSH, and testosterone in men contradict the 4-week data from the Rakhmatullaeva study.

Sponsor's Claim: Nebivolol did not affect basal, non-stimulated LH, prolactin, or testosterone levels in men and women in the 7-day NEB-BEL-52 study. Nebivolol did not affect basal, non-stimulated FSH, LH, estradiol, prolactin, or testosterone levels in men in the 7-day NEB-BEL-55 study.

DMEP Response: These were only short-term studies using 5 mg/day nebivolol and do not rule-out an effect of long-term nebivolol on these parameters. The lack of difference in estradiol levels in BEL-55 cannot be definitely concluded because in this cross-over study there was a carry-over effect of nebivolol on estradiol levels measured at the end of the placebo treatment period for the subjects who received nebivolol first.
Sponsor's Claim: In NEB-BEL-52, there was a normal response of ACTH, cortisol, prolactin, and growth hormone to insulin-induced hypoglycemia, confirming overall integrity of the HPA.

DMEP Response: There were documented changes to the HPA axis after only 7 days of therapy with nebivolol 5 mg daily – please see response to 1a.

Sponsor's Claim: In Rakhmatullaeva's study (12-weeks of 5 or 10 mg daily nebivolol), baseline LH and FSH were significantly higher and mean baseline testosterone levels were significantly lower in a group of hypertensive men compared with normotensive controls. At the end of treatment, mean values for these hormones in patients with hypertension approached the baseline values of the control group.

DMEP Response: Please see responses to 1a and 1f.

e. If none of the above studies are sufficient to rule out a possible endocrine effect of nebivolol in humans, what are our recommendations for further testing or clinical trials in humans to better determine this?

DMEP Response: We recommend a randomized, well-designed study of 3 months duration testing up to the 10 mg recommended maximum dose of nebivolol in both men and women. Comparison could be to placebo and to an active treatment (e.g. another commonly used beta-blocker, such as atenolol). Compliance with study medication should be assessed to ensure adequate nebivolol exposure. This study should collect bloods for hormones at the appropriate time of the day and the appropriate time of the menstrual cycle. Detailed methods of hormone collection and analyses should be presented. In addition to basal, unstimulated hormone levels, provocative testing should be performed to more fully test the reserve of the hormonal system (where appropriate) with long-term nebivolol use. For the cortisol response, relying solely on a high-dose ACTH test is inadequate. Other testing (e.g. insulin-induced hypoglycemia, low-dose ACTH test) should also be performed. Free sex-hormones concentrations should be measured in addition to total sex-hormone levels. Finally, the clinical significance of changes in the hormonal parameters should be assessed (e.g. sexual dysfunction questionnaire, menstrual changes, etc.).

f. In the Rakhmatullaeva study, nebivolol decreased luteinizing hormone (LH) and follicle stimulating hormone (FSH) and increased testosterone. Rakhmatullaeva attributes this finding to the antihypertensive effect of nebivolol. Do we agree or do these changes reflect nebivolol's endocrine effect in humans?

DMEP Response: Assuming the results are valid, it is not possible to determine from the Rakhmatullaeva study whether the changes in LH, FSH, and
testosterone are due to the anti-hypertensive effect or an endocrinologic effect of nebivolol. Furthermore, the positive 4-week findings in this study contrast with the null 4-week testosterone results in NEB-CAN-09. Therefore, we would consider the results from this study as “hypothesis-generating” and recommend confirmation in a well-designed trial. Such a trial could compare the LH, FSH, and testosterone effects of nebivolol to that of another anti-hypertensive agent that does not alter these parameters and also capture clinical information regarding hypogonadal symptoms.

2. In the 13 week study in mice and rats (Appendix 7), there appears to be a significant dose-related decrease in the percentage of normal sperm and sperm count in the mouse. There was also a significant dose-dependent increase in adrenal and prostate weight and a significant decrease in the weight of the seminal vesicles that did not completely normalize during recovery. Dose-dependent Leydig cell hyperplasia was noted. LH increased significantly and estradiol decreased by Week 13 in the nebivolol 40 mg/kg/day mouse model. Several estradiol measurements were not obtained because they were apparently below the limit of quantification of the assay. Is the assay adequate for appropriately interpreting the changes in estradiol seen in this study? Do these study results rule out a possible endocrine effect of nebivolol?

**DMEP Response:** Defer to Pharmacology-toxicology.

3. Do we agree that nebivolol exerts no unique or clinically relevant adverse effects on adrenal function at therapeutic dosing regimens?

**DMEP Response:** No. There is a signal from the 7-day insulin study (BEL-52) suggesting that nebivolol may affect the integrity of the HPA axis. Methodological issues with most of the studies limit conclusions and do not assure us that the endocrinologic profile of nebivolol has been adequately studied.

4. Do we agree that the pre-clinical reproductive tract observations are not clinically relevant?

**DMEP Response:** Defer to Pharmacology-toxicology.

5. Do we agree that the reproductive/developmental toxicity profile of nebivolol is consistent with the beta-antagonist class?

**DMEP Response:** Defer to Pharmacology-toxicology.
References:


This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Hylton Joffe
3/7/2006 11:15:33 AM
MEDICAL OFFICER

Mary Parks
3/7/2006 12:11:19 PM
MEDICAL OFFICER
Memorandum

To: File: NDA 21-742 nebivolol—— for hypertension
   Stockbridge, Norman: Acting Director, HFD-110

From: Director, ODEI

Date: June 21, 2005

Subject: Nebivolol

Nebivolol is a long-marketed (European) beta blocker with some in vitro
cardioselectivity and complex, incompletely studied metabolism. As all reviewers
indicate, the striking increase in leydig cell tumors in mice must be “explained”
before N can be approved. There may indeed be an “endocrine mechanism,” but
this needs to be established and shown to be irrelevant to humans. I note also
that there is not yet an acceptable trade name.

There are, I believe 3 issues of interest: cardioselectivity, the presence of
active metabolites and complex mixtures of parents (both isomers) and
metabolites and subset differences in response. Given the flat dose-response, I
am not concerned about the second of these but the situation could make
assessment of cardioselectivity difficult.

1. Cardioselectivity

Based on Dr. Hicks’ reviews (pg 68) of supportive studies, it appears that
essentially all beta-1 blockade is contributed by d-N with little by L-N, and that
it is quite selective (250-350 fold). In the past we have required studies in
asthmatics (single dose) showing a smaller effect on airway resistance for a
drug seeking a “cardioselective” claim. There is in fact a study (GBR-22) in
normals examining the effect of N atenolol and propanolol on specific airway
conductance (SGaw), showing less effect by N. We need to decide whether
this study provides sufficient evidence for a cardio-selective claim.

2. Complex Metabolites

Given the 2D6 metabolism and active metabolites, and the marked affect of
hepatic failure on AUC, it could be very difficult to know how any individual
would respond to N. Fortunately, and like most beta blockers, the DIR for BP
is pretty flat, over a 30 fold range in the case of N, so these concerns are
clinically minimal. It would therefore be of interest to study DIR for
summarized beta blockade i.e., capturing effects of both parents and
metabolites using steady state exercise HR or, conceivably, isoproterenol infusions, in normals and 2D6 poor metabolizers over the dose range of 1.25 to 30-40 mg. In fact there is an isoproterenol infusion study (Hicks pg 75), showing increasing effects of N 5, 10 and 20 mg, pretty similar to atenolol and propranolol, as well as an exercise study (Hicks pg 76), in which I-N had no effect on an exercise induced heart rate increase, indicating little or no activity. In another study I-N had no effect at all on HR and BP. It thus seems fairly clear that the seemingly complex situation may be simpler than it first appears. The I-isomer may have little activity. I could not find data on the metabolites, but as noted, over the 5-20mg range, N looks like any other BB.

3. Racial and other subset differences in response

The DIR for S/D pressure in 4 studies is shown in the table below (from Karkowsky review)

<table>
<thead>
<tr>
<th>Studies</th>
<th>Change in BP (S/D), plbo – subtracted, sitting</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose 1.25 2.5 5 10 20 40</td>
</tr>
<tr>
<td>302 12 week n=909 PM=6.5% BP=60 909 Mean baseline=100</td>
<td>83 82 165 166 166 166</td>
</tr>
<tr>
<td>305 12 week n=807 PM=6.2% BP=60</td>
<td>244 244 244</td>
</tr>
<tr>
<td>202 12 week N=300 PM=2% BP=60</td>
<td>49 50 51 50 51</td>
</tr>
<tr>
<td>321 12 week n=669 PM=5.4% BP=60</td>
<td>168 168 166</td>
</tr>
<tr>
<td></td>
<td>1.5/2.9 2.6/4.9 6.0/6.1 7.3/6.0 6.8/5.5</td>
</tr>
<tr>
<td></td>
<td>5.7/3.2 3.7/3.3 6.2/4.7</td>
</tr>
</tbody>
</table>
Although study 302 could suggest that although doses of 1.25 and 2.5 mg are effective in whites, 5mg is needed for blacks, and your figure could also suggest that the difference all turns on two data points in study 302, and study 305 in a mixed population looks very similar to 202. Probably 2.5-5mg, or even 10mg, is a reasonable starting dose for both races. There seems little consequence (see safety discussion below) to such a starting dose and needless titration simply delays control. If we agree that there is clear evidence of cardioselectivity, the higher starting dose might be a problem. As noted, peak and trough effects are essentially identical, even at low doses (Incidentally, I get peak/trough of 0.74 for study 302, dose 1.25 for sitting DBP, not the 1.4 Dr. Karkowsky has on pg 19; the 2.5 dose is similar. The reason is that the values in his table 9 are trough to peak, not peak to trough. See e.g., Hicks review pg 136).

As Dr. Karkowsky notes, there seems to be little effect of age (≤65 vs > 65) gender, or even metabolizer status an adverse effects.

As Dr. Karkowsky notes, there were 2 deaths (ANII, sudden death post pericarditis). Neither suggest a role for N. The discontinuation table and serious event table do not suggest increasing rates with dose, conceivably excessive brochycardia (at 20mg). There was, as noted, a single case of angioedema (no ACEI), but also some cases in the Janssen database. The 3 cases of liver disease (Lemtouni) do not suggest a drug relationship. I note that there was an attempt at a thorough QT that did not manage more than 3/70 PMs, and that used a maximum dose of 40mg. Although I believe the 3 days at dose probably did get close to steady state for parent drug (> 4 half lives), that does not exactly stress the system, but the data captured from the clinical trials are pretty reassuring (QTc by Bazett or Fridericia is decreased compared to placebo).

For non-serious ADR’s, there is a suggestion that headache, diarrhea, and fatigue may be drug-induced.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Robert Temple
6/21/05 09:21:00 PM
MEDICAL OFFICER
DIVISION OF REPRODUCTIVE AND UROLOGIC DRUG PRODUCTS

Response to Consultation Request

Consult Date  May 24, 2005

To  Karen Hicks, M.D.
     Medical Officer HFD 110

From  Audrey Gassman, M.D.
       Medical Officer HFD 580

       Lynnda Reid, PhD
       Pharmacology/Toxicology Team Leader HFD 580

Through  Shelley R. Slaughter, M.D., Ph.D.
          Team Leader, HFD 580

       Daniel Shames, M.D.
       Director, Reproductive and Urologic Drug Products, HFD 580

Subject  Response to Consultation Request from Division of Cardiorenal Drug Products (HFD-110) dated December 21, 2004, regarding the reproductive toxicology of Nebivolol, a beta-1 antagonist being developed for the treatment of mild to moderate hypertension.

Introduction

The Division of Cardiorenal Drug Products (HFD-110) has sent a Request for Consultation to the Division of Reproductive and Urologic Drug Products (HFD-580) requesting our advice concerning Nebivolol, a beta-1 antagonist being developed for the treatment of hypertension. Nebivolol will be used chronically, and the dosing will range from a starting dose of 2.5 mg daily to 20 mg daily. The specific questions posed from HFD-120 are:

1. How would one develop a study to further evaluate cyclicity in female mice and rats (and to rule out a stress-induced effect)? What study duration is required? Does cyclicity need to be evaluated in male rodents as well, and do we also need to be concerned about stress-induced effects in male rodents?

2. There is a concern that Nebivolol administration to women may result in disrupted cyclicity. Given this, what specific parameters would need to be followed in a future study? Could these parameters be evaluated in Protocol 324? Since men do not "cycle," am I correct in assuming no further testing in men would be required?

June 21, 2005
Materials Reviewed

Materials reviewed were from a brief Pharmacology/Toxicology Email Review of studies contained in IND 33,060 dated 19-May-05, and a Medical Officer’s Review dated 30-Apr-04.

Brief Background

Janssen Pharmaceutica Products, L.P., Bertek Pharmaceuticals, Inc., and A. Menarini LTD developed nebivolol. In the late 1980s and early 1990s, Janssen performed approximately 65 clinical trials in 2874 patients in the United States and Europe. According to the sponsor, 2,570 of these 2,874 patients received nebivolol for the treatment of hypertension. Most of the nebivolol doses studied were less than 10 mg; however, Janssen also studied doses up to 30 mg in short-term dose-finding studies. Approximately 400 patients received nebivolol for 12 months or longer at doses of 5 mg.

On May 1, 1998, Bertek Pharmaceuticals, Inc., a subsidiary of Mylan, assumed ownership of IND 33,060 and subsequently performed six pivotal studies with nebivolol in patients with mild to moderate hypertension in the United States, the United Kingdom, the Netherlands, and Belgium from May 2002 until present. The pivotal studies, comprised of NEB-302, NEB-305, NEB-202, NEB-321, NEB-306, and NEB-203, evaluated 2,800 patients with hypertension. A total of 2,464 out of these 2,800 patients received nebivolol in doses ranging from 1.25 mg to 40 mg. Additionally, NEB-122 studied electrocardiographic changes in 281 healthy subjects. NEB-323, performed by the sponsor, is a study assessing the safety and efficacy of long-term nebivolol exposure (up to 24 months) in patients with mild to moderate hypertension and is ongoing at the time of this NDA. For NDA 21-742, Bertek Pharmaceuticals performed and submitted 94 primary safety and efficacy studies included 6 primary studies and 62 supportive studies performed by Jannsen.

The preclinical evaluation included a number of reports where the original sponsor (Jannsen) simply states that the drug has affected cyclicity. The original applicant did not do vaginal cytology, but in the histopathology there are findings of decreased numbers of corpora lutea, increased numbers of atretic follicles, and other indicators of decreased activity. In some cases, there are changes in adrenal histology and body weight loss, but the panoply of clinical chemistry changes that one would expect to see is usually not there.

There are also reports of altered cyclicity where there are no indications of adrenal changes. In the teratogenicity studies some alterations in bone structure in both rats and rabbits were noted.

Reproductive Findings in Animals

Several of the preclinical studies may suggest that Nebivolol may affect the endocrine axis.
1. There have been statements in several study reports that the reproductive tract is one of the target organs of toxicity. One of the statements is quoted here: "The adrenocortical, ovarian and testicular changes in the 160 mg/kg dosed groups are directly related to the interference of the test article with steroid metabolism. This interference results in a hormonal imbalance as evidenced by the organ weight changes of the adrenals and the ovaries, by the swelling of the adrenals and by the severely decreased serum cholesterol levels."

Of note, the data supporting this statement were not made available to the reviewing Division.

2. Study EDMS-PSDB-2876162 reported drug-related changes in cyclic activity after 1 week of 40 mg/kg nebivolol followed by 1 week of 60 mg/kg nebivolol. There were no differences in body weight compared to the control group. There were insufficient doses in this study to assess either a dose-response effect or dependence upon adrenal changes. N88268, a one month intravenous administration study in rats showed a 9% (p<0.01) decrease in female "gonad" weight at 5 mg/kg/day. There were no associated adrenal changes, body weight changes or other indicators of stress effects. The study did not provide the data to assess cyclicity in association with the organ weight changes. Changes in female "gonad" weight and histologic changes indicative of changes in cyclicity have been reported in multiple studies. In some cases, these changes have been associated with weight loss and adrenal changes. Overall, the effects upon the female reproductive tract are incompletely characterized.

3. Dystocia has been reported in at least 3 studies (N92750, N106655, N65774) but with incidences clearly reported for only 2 studies. Dystocia has been reported to occur with doses of nebivolol ≥5 mg/kg.

4. Prolonged gestation was reported in study N92570 with increased duration of gestation 0.5 days longer than control (p<0.01) at 40 mg/kg. The report for study N106655 indicated increased duration of gestation at the HD of 20 mg/kg. The increase was 1 day longer than control (p<0.05).

5. The Segment III developmental studies are inconsistent with regard to the effects of late gestation/lactation exposure on the offspring.

Recommendations

Questions:

1. How would one develop a study to further evaluate cyclicity in female mice and rats (and to rule out a stress-induced effect)? What study duration is required? Does cyclicity need to be evaluated in male rodents as well, and do we also need to be concerned about stress-induced effects in male rodents?
The data in rodents is inconsistent and there does not appear to be any reported adverse effects on the adrenals or reproductive organs in the 12-month dog study. Although serum triglycerides and cholesterol levels were consistently decreased in rodent toxicology studies, mechanistic studies in mice demonstrated no change in ACTH stimulation, increases in testosterone levels in males, and inconsistent changes in corticosterone levels in males and females. In the multigenerational reproductive and developmental study in rats, this reviewer believes that there is no significant difference in the numbers of corpora lutea and implantations between F1 offspring exposed in utero to vehicle or Nebivolol. The fertility rate was reduced in offspring of dams treated at 5 mg; however, the cause of this reduction was not explored as to whether it was related to male or female infertility or potentially to delayed sexual maturation of the offspring.

To explore potential effects on disruption of estrus cyclicity in rodents it would be necessary to conduct a study specifically addressing this issue, preferably in female rats. Cyclicity should be monitored for at least 6 weeks. Histopathology of the adrenal glands and ovaries should be performed. If any changes in cyclicity are observed, a subset of animals should be observed to determine the time to restoration of normal estrus cycling and reversibility of any histopathology findings.

It is not necessary to evaluate cyclicity in male animals.

2. There is a concern that Nebivolol administration to women may result in disrupted cyclicity. Given this, what specific parameters would need to be followed in a future study? Could these parameters be evaluated in Protocol 324? Since men do not "cycle," am I correct in assuming no further testing in men would be required?

It is unclear what aspect of reproduction (hypothalamic, pituitary or ovarian axis) is being affected by Nebivolol, and whether these findings would be applicable to humans. A de novo clinical study to target disruption of cyclicity would be difficult to design given the limited human information available. Data obtained from previously collected clinical trial information would not be helpful as no baseline endocrinologic or menstrual diary information was collected. In addition, it would be difficult to estimate the number of patients that were reproductive aged that actually initiated treatment with normal menstrual cycles in the previously performed studies.

The Cardiorenal reviewer provided a copy of a new clinical protocol for Nebivolol. Protocol 324 is an open-label, randomized, titration to effect, multi-center study of up to 1000 patients, (18 years or older), of the safety, tolerability and blood pressure effects of metoprolol versus nebivolol alone or in combination with amlodipine or HCTZ.

Reviewer's comments: Protocol 324 could assist in determining the effect of nebivolol monotherapy on menstrual cyclicity by menstrual diary evaluations. In all reproductive age female subjects regardless of mode of contraception:
- Perform gynecological examinations including a pap smear if needed at baseline. Repeat the gynecological exam at the end of therapy.
- In order to assess treatment effects on menstrual cycles, have subjects use diaries for at least two complete cycles to record menstruation and/or irregular bleeding. If there is a disruption of the menstrual cycle, provide post treatment follow-up to document return of normal function. Subjects would need 3 to 6 months of pretreatment menstrual cycle diary data to determine their true cyclicity.
- Follow-on-treatment pregnancies for outcome information.

However, the Applicant should decide whether they wish to better characterize the effects of Nebivolol in reproductive age women in a more detailed endocrine study. The Applicant could consider a more detailed endocrine study in a subset of women to better characterize the effects of treatment on hormonal and reproductive function. This would include serum concentrations of LH, FSH, and free and total testosterone obtained early in the proliferative phase of the cycle and a serum progesterone obtained in the midluteal phase of the cycle. These profiles should be done at baseline, on treatment, and post treatment.

Men do have a very short spermatogenic cycle (90 days) that requires an intact hypothalamic-pituitary-testicular axis. However, there is no evidence from the animal studies that Nebivolol significantly impacts spermatogenesis per se. In addition, there is no evidence that the reproductive effects of Nebivolol would not be reversible in men given the short spermatogenic cycle of 90 days. Therefore, no additional studies in men should be required at this time.

Clinical Recommendations:
1. Protocol 324 could assist in determining the effect of nebivolol monotherapy on menstrual cyclicity by menstrual diary evaluations. In all reproductive age female subjects regardless of mode of contraception:
   - Perform gynecological examinations including a pap smear if needed at baseline. Repeat the gynecological exam at the end of therapy.
   - In order to assess treatment effects on menstrual cycles, have subjects use diaries for at least two complete cycles on Nebivolol treatment to record menstruation and/or irregular bleeding. If there is a disruption of the menstrual cycle, provide post treatment follow-up to document return of normal function. Prior to this, the Applicant would need to document a minimum of 3 – 6 menstrual cycles prior to the treatment cycles to determine the true cyclicity of the patient.
   - The Applicant should follow any on-treatment pregnancies for pregnancy outcomes
   - The Applicant could consider collecting the menstrual cycle data obtained with metoprolol as a control group.

2. In contrast, the Applicant should consider whether they wish to better characterize the effects of Nebivolol in reproductive age women in a more detailed endocrine study. The Applicant could consider a more detailed
endocrine study in a subset of women to better characterize the effects of treatment on hormonal and reproductive function. This would include serum concentrations of LH, FSH, and free and total testosterone obtained early in the proliferative phase of the cycle and a serum progesterone obtained in the midluteal phase of the cycle. These profiles should be done at baseline, on treatment, and post treatment. In addition to the endocrine profiles, menstrual cycle data would also be collected.

3. At this time, no male reproductive studies appear to be indicated.
4. Please feel free to reconsult us at the time of labeling negotiations.

DRUDP thanks you for the opportunity to provide consultation on the above issues. We are available to assist further if needed.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Audrey Gassman
6/21/05 11:06:57 AM
MEDICAL OFFICER

Lynnda Reid
6/21/05 11:08:49 AM
PHARMACOLOGIST

Shelley Slaughter
6/21/05 11:21:21 AM
MEDICAL OFFICER
I concur.

Daniel A. Shames
6/22/05 06:06:09 PM
MEDICAL OFFICER
DIVISION OF CARDIO-RENAL DRUG PRODUCTS
Divisional Memorandum

NDA: 21-742 (nebivolol for hypertension)
Sponsor: Bertek Pharmaceuticals
Review date: 8 May 2005
From: N. Stockbridge, M.D., Ph.D., Acting Director, HFD-110
To: Dr. Robert Temple, Director, ODE

This memo conveys my support for taking an “Approvable” action for this NDA.

For your convenience, I have extracted trough seated systolic and diastolic blood pressure data from the three doe-ranging studies. These are raw means; mostly Dr. Hicks’s review focuses mainly on the least squares estimates.

I note that the lowest dose studies, 1.25 mg, had about half of the effect of the highest dose (40 mg). The trough-peak ratio is high and does not appear to be dose-related. Race makes a small difference, but the drug works well in blacks. Extensive or poor metabolizer status makes some difference pharmacokinetically, but the dose-response is so flat that it is of little consequence.

Aside from pretty clearly supporting once-daily dosing, there is nothing particularly advantageous about nebivolol for hypertension.

As you are aware, there are two possibly related findings that warrant resolution prior to approval. The first is a dose-related increase in Leydig cell tumors in mice. Two observations suggest that these findings relate to hormonal effects. One is that the finding was not seen in rats, consistent with differences in the hormonal regulation of rats and mice. The other observation is the lack of apparent genotoxicity. On the other hand, the rate of tumorigenesis in mice was remarkable high and was manifest at exposure levels close to clinical relevance.
The second finding is of reproductive toxicity in rats, again with exposure close to the clinically relevant levels.

These are unusual findings for a beta-blocker.

The sponsor and the review team have been in numerous discussions with the sponsor developing a plan to resolve these issues. As Dr. Kackowsky's memo summarizes, there are two parts to such a plan. The first is to develop an understanding of the endocrinological correlates of the phenomena in the affected species and the second part is to show that the endocrine effects do not occur in man. The animal studies are underway, I believe, without implementing a late suggestion to include another beta-blocker.

Labeling negotiations have simply avoided the pharm-tox section.

There appears to be no ongoing development program for another indication.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Norman Stockbridge
5/9/05 10:18:51 AM
MEDICAL OFFICER
CLINICAL REVIEW: ALL INDIVIDUAL SUPPORTIVE STUDIES

Application Type  NDA
Submission Number  21,742
Submission Code  000

Letter Date  April 29, 2004
Stamp Date  May 4, 2004
PDUFA Goal Date  February 28, 2005

Reviewer Name  Karen A. Hicks
Review Completion Date  January 21, 2005

Established Name  Nebivolol
(Proposed) Trade Name  ——
Therapeutic Class  Selective β1 blockade
Applicant  Bertek Pharmaceuticals, Inc.

Priority Designation  S

Formulation  PO
Dosing Regimen  2.5 mg, 5 mg, 10 mg
Indication  Hypertension
Intended Population  Adults
Table of Contents

1 Review of Individual supportive studies.......................... 19

1.1 Report Number: 1270_01_00. ("Comparative Effects of Nebivolol, Nebivolol Enantiomers, AtENOLOL, Metoprolol, Carvedilol, and Bucindolol on Human Endothelial Cell Nitric Oxide Release Following Acute Treatment") (June 25, 2002) (Reviewer: Karen A. Hicks, M.D.).......................................................... 54

1.2 Report Number: 1273_01_00. ("Comparative Effects of Nebivolol, Nebivolol Enantiomers, and Six Nebivolol Metabolites on Endothelial Nitric Oxide Release from Human Endothelial Cells following Acute Treatment") (July 25, 2002) (Reviewer: Karen A. Hicks, M.D.).......................................................... 57

1.3 Report Number: 1332_00_00. ("Comparative Effects of Nebivolol Metabolites 4,5'-dihydroxy, 4,8'-dihydroxy, Glucuronide, Nebivolol, and Nebivolol Enantiomers on Endothelial Nitric Oxide Release in Human Endothelial Cells following Acute Treatment") (March 2003) (Reviewer: Karen A. Hicks, M.D.).......................................................... 59

1.4 Report Number: 1333_00_00. ("Comparative Effects of Nebivolol and Atenolol on Nitric Oxide Release from Human Endothelial Cells following Chronic Treatment") (August 2, 2002) (Reviewer: Karen A. Hicks, M.D.).......................................................... 61

1.5 Report Number: 1334_00_00. ("Comparative Effects of Nebivolol and Atenolol on Nitric Oxide Release in Black and Caucasian Endothelial Cells following Chronic Treatment") (September 20, 2002) (Reviewer: Karen A. Hicks, M.D.).......................................................... 62

1.6 Report Number: 1271_00_00. ("Effects of Nebivolol and ACE-Inhibitors on Endothelial Nitric Oxide Release in Black and Caucasian Donor Endothelial Cells following Chronic Treatment") (May 2003) (Reviewer: Karen A. Hicks, M.D.).......... 63

1.7 Report Number: 1269_01_00. ("Separate and Combined Effects of Nebivolol and ACE-Inhibitors on Human Endothelial Cell Nitric Oxide Release following Acute Treatment") (August 5, 2002) (Reviewer: Karen A. Hicks, M.D.).......................................................... 64

1.8 Report Number: 1268_01_00. ("Effects of Acute Nebivolol Treatment on Nitric Oxide Release and Vascular Function in Normal versus Diseased Mesenteric Arteries") (September 2, 2002) (Reviewer: Karen A. Hicks, M.D.).......................................................... 66

1.9 Report Number: 1312_01_00. ("Adrenergic Receptor Pharmacology of Nebivolol in the Human Heart") (February 9, 2004) (Reviewer: Karen A. Hicks, M.D.).......................................................... 68

1.10 Report Number 1311_01_00. ("Adrenergic Receptor Pharmacology of Nebivolol, Its Enantiomers and Nine Metabolites in the Human Heart") (February 9, 2004) (Reviewer: Karen A. Hicks, M.D.).......................................................... 70


2


LMD No. 49278. Study ID: N/A. ("Effect of a Single Oral Intake of R 67555 (5 mg and 10 mg) and of a 7-Day Intake of R67555 (5 mg/day) on ECG. Clinical Research Report. February 1986") (Years of the Study: Not Recorded) (Reviewer: Karen A. Hicks, M.D.) ................................................................. 95


LMD No. 64808. Study ID: BEL-19. ("Effect of Nebivolol 10 mg and 20 mg versus Placebo on Heart Rate, Blood Pressure, Systolic Time Intervals and Side Effects. A
.................................................................................................................. 101


1.31 LMD No. 54549. Study ID: BEL-30. ("Hemodynamic Effects of a Single Oral Administration of R65824 (Nebivolol), a New Selective Beta-1-Adrenoreceptor Blocking Agent in Human Volunteers as Compared to the Effects of Atenolol, Pindolol and Propranolol") (Source: Clinical Research Report NEB-BEL-30, September, 1985 and Study Publication. No protocol was submitted.) (Reviewer: Shari Targum, M.D.) .......................... 122


1.33 LMD No. 59056. Study ID: BEL-1/Part II. ("Double-Blind Placebo-Controlled Study Comparing the Haemodynamic Effects of Various Doses of Nebivolol During Subacute Treatment. Clinical Research Report NEB-BEL-1. June 1987") (No protocol was submitted.) (Reviewer: Shari Targum, M.D.) .......................... 129

1.34 LMD No. 59580. Study ID: N/A. ("Randomized Cross-Over Study Comparing the Haemodynamic Effects During Exercise of a Single Administration of Nebivolol 0.5 mg I.V., 5 mg Tablet and 5 mg Solution in Healthy Volunteers. Clinical Research Report. March 1987") (No protocol was submitted) (Reviewer: Shari Targum, M.D.) .......................... 133

1.36 LMD No. 59922. Study ID: BEL-38. ("Acute Hemodynamic Effects of 2 Enantiomers of Nebivolol (R 67138 and R 67145) in Mean at Rest and During Exercise. Clinical Research Report NEB-BEL-38. March 1988") (No protocol was submitted.) (Study Period: March – May, 1987) (Reviewer: Shari Targum, M.D.) 141

1.37 LMD No. 59970. Study ID: BEL-36. ("Double-Blind Study Comparing the Subacute Hemodynamic Effects in Men at Rest and During Exercise of the 2 Enantiomers of dl-Nebivolol, d-Nebivolol (R67138) and l-Nebivolol (R67145). Clinical Research Report NEB-BEL-36. March 1988") (No protocol was submitted.) (Reviewer: Shari Targum, M.D.) ........................................................................................................ 143

1.38 LMD No. 64858. Study ID: RSA-1. ("The Effects of Nebivolol on Heart Rate and Blood Pressure at Rest and During Exercise. A Dose Finding Study. Clinical Research Report NEB-RSA-1") (Source: Study Report, undated. No protocol was submitted. According to the report, the study started October 1, 1989 and ended (implausibly) on February 28, 1989) (Reviewer: Shari Targum, M.D.) ........................................... 145

1.39 LMD No. 65577. Study ID BEL-9. ("Effects of Isometric Handgrip on Blood Pressure and Heart Rate During a 14-Day Double-Blind Cross-Over Treatment with Nebivolol and Atenolol in Healthy Volunteers") (September 8, 1987 – April 27, 1988) (Reviewer: Karen A. Hicks, M.D.) ........................................................................................................ 147


1.42 LMD No. 68099. Study ID: RSA-5. ("The Effects of Nebivolol on Heart Rate and Blood Pressure at Rest and During Exercise. A Sub-Acute Dose Finding Study. Clinical Research Report NEB-RSA-5") (Source: study report. No protocol was submitted) (Reviewer: Shari Targum, M.D.) ........................................................................................................ 163


1.44 LMD No. 88260. GBR-19. ("The Effect of Nebivolol on Heart Rate, Blood Pressure, and Cardiac Output at Rest and During Exercise in Healthy Volunteers. February 1991") (Trial Period: April 1, 1988 – February 28, 1989) (Reviewer: Karen A. Hicks, M.D.) ........................................................................................................ 172


1.47 LMD. No. 106918. Study ID BEL-25(b). ("Comparison of the Metabolic Effect of Nebivolol and Atenolol During Dynamic Exercise Part 2: In Patients with Borderline


1.51 LMD No. 59898. Study ID N/A. ("Haemodynamic Effects of Subacute Treatment with Nebivolol: A Comparison Between Poor and Normal Metabolizers. February 1988") (Reviewer: Karen A. Hicks, M.D.) ........................................................................ 183


1.53 LMD No. 62269. Study ID BEL-4/Part II. ("Effect of an 8-Day Intake of Nebivolol 5 mg/day on ECG in 6 Poor and 6 Normal Metabolizers. Part II. Clinical Research Report NEB-BEL-4. May 1988") (Reviewer: Karen A. Hicks, M.D.) ........................................................................ 190


1.62 LMD No. 107425. Study ID N/A. ("A Study to Assess the Effects of Nebivolol on Sedation and Psychomotor Performance") (Reviewer: Karen A. Hicks, M.D.) .................. 236


1.66 LMD No. 49643. Study ID N/A. ("Randomized Double-Blind Cross-Over Study of the Effects of Topical R67555 as Compared with Timolol on the Intraocular Pressure, Blood Pressure and heart Rate in Human Healthy Volunteers. April 1986") (Reviewer: Karen A. Hicks, M.D.) .................................................. 257

1.67 LMD No. 51686. Study ID N/A. ("Randomized Double-Blind Cross-Over Study of the Effects of Topical R67555 as Compared with R67555 Solvent and Timolol, on the Intraocular Pressure, Blood Pressure, and Heart Rate in Human Healthy Volunteers. July 1986") (Reviewer: Karen A. Hicks, M.D.) .................................................. 263

1.68 LMD No. 46816. Study ID N/A. ("Safety Data After Oral Administration of R65824 5 mg/day for 7 Consecutive Days in 6 Human Volunteers. December 1985") (Reviewer: Karen A. Hicks, M.D.) .................................................. 269

1.69 LMD No. 46817. Study ID N/A. ("Safety Data After a Single Oral Administration of 5 mg and 10 mg of R65824 in 8 Human volunteers. December 1985") (Reviewer: Karen A. Hicks, M.D.) .................................................. 270
1.70 (Corresponds to Study #73 in Table 1) LMD No. 84315. Study ID: USA-3, ("Double-Blind, Placebo-Controlled Study of Nebivolol 30 mg in Hypertensive Patients. Clinical Research Report NEB-USA-3. February 1991") (Reviewer: Katharine R. Lillie, M.D.) ................................................................. 277

1.71 (Corresponds to Study #76 in Table 1) LMD No. 101044. Study ID: BEL-3/6. ("Double-Blind, Placebo-Controlled, Multicentre Trial with Oral nebivolol 2.5, 5 and 10 mg Once Daily in Essential Hypertension, Followed by an Open Nebivolol 5 mg Treatment for Up to 4 Years. Clinical Research Report NEB-BEL-3/6. November 1993.") (Reviewer: Katharine R. Lillie, M.D.) ................................................................. 282

1.72 (Corresponds to #134 in Table 2). LMD NO. N/A. Study ID: NEBI-0126. ("Single-Dose, Dose-Proportionality Pharmacokinetic Study of Nebivolol Hydrochloride in Healthy Volunteers Characterized According to Their Metabolizing Status") (Trial Period: August 11, 2001 – 22 September 22, 2001) (Study Report Dated October 31, 2001) (Reviewer: Karen A. Hicks, M.D.) ........................................................................... 291
Table of Tables

Table 1. List of Supportive Studies (all reviewed) ............................................................. 20
Table 2. Clinical Pharmacology Studies (all reviewed) ...................................................... 40
Table 3. Relative Magnitude of NO Bioavailability for Nebivolol, Its Enantiomers, and Major Metabolites ................................................................. 59
Table 4. Data Summary of Nebivolol Binding Constants with Incubations at 2 and 4 Hours .... 69
Table 5. Binding Parameters ($K_i$) for Multiple β-Blocking Agents in Human Cardiac Membranes ................................................................. 69
Table 6. Summary of $K_i$ Values for All Compounds in the Nebivolol Series .................... 70
Table 7. Isoprenaline (Isoproterenol) Dose Ratios for β-Adrenoceptor Antagonists ................ 73
Table 8. Summary of Results (BEL-20) ............................................................................. 77
Table 9. GBR-28 Drug Regimen ....................................................................................... 83
Table 10. GBR-27 Study Regimen .................................................................................... 85
Table 11. Efficacy Results (GBR-27) ................................................................................ 87
Table 12. Medication Regimen (GBR-31) ......................................................................... 88
Table 13. Schedule of Evaluations/Procedures (GBR-31) .................................................. 89
Table 14. Summary of Absolute Blood Flow Results (GBR-31) ......................................... 89
Table 15. Efficacy Results (GBR-31) ................................................................................ 90
Table 16. Main Features of the Trial Sample and Summary of the Results (SWE-5) .......... 92
Table 17. Mean (SD) Plasma Concentrations of $l$- and $d$-Nebivolol Plus Their Hydroxylated Metabolites (SWE-5) ................................................................. 93
Table 18. Mean (SD) Pharmacokinetic Parameters of $l$- and $d$-Nebivolol Plus Their Hydroxylated Metabolites (SWE-5) ................................................................. 93
Table 19. Nebivolol Plasma Concentrations (SWE-5) ........................................................ 94
Table 20. Safety Results (SWE-5) ..................................................................................... 95
Table 21. Heart Rate and ECG Intervals on a Control Day and Before and 3 and 6 Hours After Intake of 5 mg and 10 mg of R 67555 (LMD No. 49278) ........................................... 96
Table 22. Heart Rate and ECG-Intervals Before, During, and After a 7-Day Intake of R 67555 (5 mg/day) ................................................................................. 97
Table 23. Individual and Mean Values of Haemodynamic Data Before Nebivolol Administration in 8 Healthy Volunteers (LMD No. 59987) ......................................................... 98
Table 24. Individual and Mean Values of Haemodynamic Data After Intravenous Administration of Nebivolol in 8 Healthy Volunteers (LMD No. 59987) ......................... 98
Table 25. Individual and Mean Values of Haemodynamic Data After Peroral Administration of Nebivolol in 8 Healthy Volunteers ......................................................... 99
Table 26. Effect of a Single Oral Intake of Placebo, Nebivolol 10 mg and Nebivolol 20 mg on Heart Rate, Blood Pressure, ECG- and Systolic Time Intervals in 12 Healthy Volunteers (BEL-19) .............................................................................. 102
Table 27. Side-Effects of 12 Volunteers at 3 Hours, 6 Hours, and 24 Hours after Intake of a Single Dose of Placebo, Nebivolol 10 mg, and Nebivolol 20 mg (BEL-19) ................. 104
Table 28. Effect of a 1-Week Double-Blind Placebo-Controlled Cross-Over Treatment with Nebivolol 5 mg O.D. on Heart Rate, Blood Pressure, ECG-, and Systolic Time Intervals in 10 Healthy Volunteers (BEL-17) .............................................................................. 106
Table 29. Systolic Blood Pressure During a 3-Minute Isometric Handgrip Test on a Control Day and After 7 Days of Treatment with dl-Nebivolol, l-Nebivolol, d-Nebivolol and Atenolol in 7 Healthy Volunteers ................................................................. 111
Table 30. Diastolic Blood Pressure During a 3-Minute Isometric Handgrip Test on a Control Day and After 7 Days of Treatment with dl-Nebivolol, l-Nebivolol, d-Nebivolol and Atenolol in 7 Healthy Volunteers ........................................................................ 112
Table 31. Heart Rate During a 3-Minute Isometric Handgrip Test on a Control Day and After 7 Days of Treatment with dl-Nebivolol, l-Nebivolol, d-Nebivolol and Atenolol in 7 Healthy Volunteers ............................................................ 113
Table 32. Efficacy Results (BEL-32, Study 2) ........................................................................ 114
Table 33. Systemic Blood Pressure and Heart Rate Before, During, and After a Treatment with l-Nebivolol 2.5 mg O.D. and a Combination of Atenolol 100 mg O.D. and l-Nebivolol 2.5 mg O.D. in 16 Healthy Volunteers (BEL-21) ..................................................................................................................................................... 116
Table 34. Systolic Time Intervals Before, During, and After a Treatment with l-Nebivolol 2.5 mg O.D. and a Combination of Atenolol 100 mg O.D. and l-Nebivolol 2.5 mg O.D. in 16 Healthy Volunteers ....................................................................................... 117
Table 35. ECG-Intervals Before, During, and After a Treatment with l-Nebivolol 2.5 mg O.D. and a Combination of Atenolol 100 mg O.D. and l-Nebivolol 2.5 mg O.D. in 16 Healthy Volunteers ....................................................................................... 118
Table 36. Results (NED-7), Mean Values (SEM) ......................................................................... 119
Table 37. Radionuclide Ventriculography Efficacy Results (USA-2) ........................................... 121
Table 38. Cardiac Doppler-Echocardiography Results (USA-2) .................................................. 122
Table 39. Mean (SEM) PEPc/LVETc During a Control Day and at 0, 3, and 6 Hours after Nebivolol Dosing ................................................................................................................................. 127
Table 40. Mean (SEM) Pre- and Post-Exercise LVET During a Control Day and at 3 and 6 Hours after Nebivolol Dosing ........................................................................................................................................... 128
Table 41. Mean (SEM) Resting LVETc, QS2c and Heart Rate, 6 Hours After Dosing on Days 7 and 14 (BEL-1/Part II) ....................................................................................................................... 132
Table 42. Mean (SEM) LVETc (msec) Before and After Exercise, 6 hours after Dosing on Days 7 and 14 ......................................................................................................................................................... 133
Table 43. Change in LVETc Post-Pre Exercise, 3 and 6 Hours After Dosing .................................. 136
Table 44. BP and HR During Submaximal Steady-State Exercise .................................................. 146
Table 45. Mean Values (±SEM) of Blood Pressure and Heart Rate During Handgrip Power Test Before and After a 2-Week Treatment with Nebivolol or Atenolol in 14 Volunteers (BEL-9) .............................................................................................. 148
Table 46. Correction to Heart Rate of 72 for PEP, LVET, and QS2 for a Group of Normal Subjects and Different Groups of Patients with Cardiovascular Diseases, According to Our Resting Supine Regression Equations .......................................................................... 151
Table 47. Mean Values of the Ratio PEPc/LVETc on a Control Day and After an Acute Oral Administration of Different β-Adrenoceptor Antagonists in 8 Volunteers ........................................................................ 152
Table 48. Mean Values ±SE of the Pre-Post Exercise LVETc (msec) on a Control Day and 3 Hours After an Acute Oral Administration of Different β-Adrenoceptor Antagonists .... 152
Table 49. Correlations Between Changes of STI and ERNA During Treatment with Atenolol 100 mg O.D. and Nebivolol 5 mg O.D. in 14 Healthy Volunteers ........................................................................ 156
Table 50. Mean Values SE of All Parameters of Blood pressure, Heart Rate, STI, and ERNA Before and After a 14-Day Treatment with Atenolol 100 mg O.D. and Nebivolol 5 mg O.D. in 14 Volunteers .................................................. 157
Table 51. Baseline Characteristics (BEL-15) ........................................................................... 160
Table 52. Efficacy Results (BEL-15) ................................................................................. 161
Table 53. Effects on Resting Heart Rate and Blood Pressure (RSA-5) ......................... 164
Table 54. Effects on HR/BP during exercise ........................................................................ 167
Table 55. Main Features of the Trial Sample (SWE-1) ......................................................... 169
Table 56. Efficacy Results (SWE-1) ................................................................................... 169
Table 57. Haemodynamic Variables at the Highest Comparable Workload (Mean and SEM) (N.B. The Highest Comparable Workload was Different for heart Rate (HR) as Compared to Systolic Blood Pressure (SBP) and Rate Pressure Product (RPP). (SWE-1) ................. 171
Table 58. Efficacy and Safety Results (BEL-25 (a)) .......................................................... 175
Table 59. Study Results (BEL-16) ..................................................................................... 177
Table 60. Safety Results (INT-2) ....................................................................................... 179
Table 61. Response Rate (INT-2) ....................................................................................... 179
Table 62. Clinical Findings/Efficacy Results (INT-2) ......................................................... 180
Table 63. Adverse Events (GBR-4) ..................................................................................... 182
Table 64. Safety Results (GBR-4) ....................................................................................... 182
Table 65. Efficacy Results (GBR-4) ................................................................................... 183
Table 66. Mean Heart Rate and Systolic Blood Pressure Before, During, and After Exercise Testing on a Control Day and Day 7 or 14 of a Subacute Treatment Period with Nebivolol 5 or 10 mg/day in 14 Normal and 7 Poor Metabolizers ......................................................... 184
Table 67. Exercise-Induced Increase of Heart Rate Before, During, and After Discontinuation of An 8-Day Treatment with Nebivolol in 6 Poor and 6 Normal Metabolizers (BEL-4/Part I) .............................................................................................................. 187
Table 68. Exercise-Induced Increase of Systolic Blood Pressure, Before, During, and After Discontinuation of An 8-Day Treatment with Nebivolol in 6 Poor and 6 Normal Metabolizers (BEL-4/Part I) ............................................................. 188
Table 69. Heart Rate and ECG-Intervals measured Before, During, and After a 8-Day Intake of Nebivolol in 6 Poor and 6 Normal Metabolizers (BEL-4/Part II) .............................................................................................................. 191
Table 70. Study Plan (BEL-52) .......................................................................................... 193
Table 71. Safety Results (BEL-52) ..................................................................................... 194
Table 72. Efficacy Results (BEL-52) .................................................................................. 194
Table 73. Changes in Steady State Hormone Levels Immediately Prior to Insulin Administration (t = 0 min) (BEL-52) ............................................................................................................. 195
Table 74. Changes in Plasma Cortisol Levels (μg/l) During the Insulin Provocation Tests (BEL-52) .................................................................................................................. 196
Table 75. Changes in 24-h Urinary Hormone Levels (BEL-52) ............................................. 196
Table 76. Assessments (BEL-39) ....................................................................................... 197
Table 77. Results (BEL-39) .............................................................................................. 199
Table 78. Parameters for Diabetic Control: Statistics (BEL-39) ........................................... 200
Table 79. Safety Results (BEL-39) ..................................................................................... 200
Table 80. Mean Blood Viscosity at Shear Rate (BEL-39) ...................................................... 201
Table 81. Sitting and Standing Blood Pressure: Statistics (BEL-39) ..................................... 201
Table 82. Sitting and Standing Heart Rate: Statistics (BEL-39) ............................................ 202
Table 83. ECG Parameters: Statistics (BEL-39) ................................................................. 202
Table 84. Haematology, Biochemistry, and Urinalysis: Descriptive Statistics and Changes from Baseline to End of an 8 Week Treatment Period with Nebivolol (BEL-39) ...................... 203
Table 85. Hormonal Levels: Statistics (BEL-55) ................................................................. 205
Table 86. Study Assessments (ITA-5) ............................................................................. 207
Table 87. Co-Existing Disease (ITA-5) ............................................................................ 208
Table 88. Concomitant Medication (ITA-5) ...................................................................... 208
Table 89. Blood Pressures from Baseline (ITA-5) ............................................................. 209
Table 90. Efficacy Study Results (ITA-5) ......................................................................... 209
Table 91. Blood Count/Blood Chemistry/Urinalysis: Descriptive Statistics and Changes During Treatment (ITA-5) .......................................................... 210
Table 92. Supine Heart Rate (ITA-5) ................................................................................. 211
Table 93. Standing Heart Rate (ITA-5) .............................................................................. 212
Table 94. Safety Results: ITA-5 ..................................................................................... 212
Table 95. Assessments (CAN-7) ..................................................................................... 213
Table 96. Efficacy Results (CAN-7) ................................................................................. 214
Table 97. Mean Serum Glucose, Insulin, and C-Peptide Observed Before and After 3 Months of Nebivolol or Atenolol Treatment Following an oral Glucose Tolerance Test (OGTT) (CAN-7) ............................................................................. 215
Table 98. Mean Sitting Systolic and Diastolic Blood Pressure Before and After 2, 4, 8, and 12 Weeks of Nebivolol or Atenolol Treatment (CAN-7) .............................................................. 216
Table 99. Mean Standing Systolic and Diastolic Blood Pressure Before and After 2, 4, 8, and 12 Weeks of Nebivolol or Atenolol Treatment (CAN-7) .............................................................. 216
Table 100. Mean Heart Rate Before and After 2, 4, 8, and 12 Weeks of Nebivolol or Atenolol Treatment ...................................................................................................................... 217
Table 101. Adverse Events Definitively Related to Drug Treatment ................................ 217
Table 102. Safety Results (CAN-7) .................................................................................. 218
Table 103. Endocrine Profile Summary Values Observed Before and After 3 Months of Nebivolol or Atenolol Treatment ...................................................................................... 219
Table 104. Study Assessments (CAN-8) ......................................................................... 221
Table 105. Glucose/Insulin Homeostasis - Euglycemic-Hyperinsulinemic Clamp Test........ 222
Table 106. Glucose/Insulin Homeostasis - Intravenous Glucose Tolerance Test (CAN-8) .... 223
Table 107. Clinic Blood Pressure and Heart Rate (CAN-8) ................................................ 225
Table 108. Ambulatory Blood Pressure and Heart Rate (CAN-8) ....................................... 225
Table 109. Maximal Oxygen Uptake Test (CAN-8) ......................................................... 229
Table 110. Systemic Haemodynamics - Aerobic Exercise (CAN-8) ................................. 230
Table 111. Regional Haemodynamics - Isometric Exercise (CAN-8) ................................. 231
Table 112. Summary of Efficacy Results (CAN-8) ............................................................ 232
Table 113. Adverse Event Summary (CAN-8) .................................................................. 233
Table 114. Overall Safety Results (CAN-8) ...................................................................... 233
Table 115. Important Laboratory Abnormalities (CAN-8) ................................................. 234
Table 116. Important Laboratory Abnormalities (Urinalysis) (CAN-8) .............................. 234
Table 117. Individual Data for Code-4 Important Laboratory Abnormalities (CAN-8) ....... 235
Table 118. Broadent Attention ......................................................................................... 237
Table 119. Randomization Scheme (GBR-14) ................................................................. 238
Table 120. Assessments (GBR-14) .................................................................................. 238
Table 121. Summary Statistics - Multiple Sleep Latency Tests (GBR-14) ...................................................... 239
Table 122. Summary Statistics (GBR-14) ........................................................................................................ 240
Table 123. Alcohol Blood Levels (AUC) Statistical Analysis (GBR-14) .............................................................. 244
Table 124. Assessments (GBR-22) .................................................................................................................. 246
Table 125. Assessments (NEB-ITA-2) .............................................................................................................. 252
Table 126. Efficacy Results: Blood Pressure (ITA-2) ....................................................................................... 253
Table 127. Efficacy Results (ITA-2) ................................................................................................................ 254
Table 128. Blood Hormonal Factors (ITA-2) .................................................................................................... 254
Table 129. Plasma Concentration of Nebivolol (ITA-2) .................................................................................... 255
Table 130. Heart Rate (ITA-2) ....................................................................................................................... 256
Table 131. Safety Results (ITA-2) .................................................................................................................. 257
Table 132. Comparison of Frequency Distributions of Laboratory Values After 7 Days of R 65824 Intake 5 mg/day with Frequency Distributions of Laboratory Values Before Tablet Intake .............................................................. 269
Table 133. Individual Laboratory Values ......................................................................................................... 270
Table 134. Comparison of Frequency Distributions of Laboratory Values 2 Hours After Intake of 5 mg of R 65824 with Frequency Distributions of Laboratory Values Before Tablet Intake ........................................................................ 271
Table 135. Comparison of Frequency Distributions of Laboratory Values 2 Hours After Intake of 10 mg of R 65824 with Frequency Distributions of Laboratory Values Before Tablet Intake ..................................................................... 273
Table 136. Individual Laboratory Values: 5 mg R 65824 ................................................................................. 275
Table 137. Individual Laboratory Values: 10 mg R 65824 ............................................................................ 276
Table 138. Main Features of the Trial Sample and Summary of the Results (USA-3) .......................................... 279
Table 139. Clinical Findings (USA-3) .............................................................................................................. 280
Table 140. Demographic Data (NEBI-0126) .................................................................................................. 293
Table 141. Mean (% CV) d-Nebivolol Pharmacokinetic Parameters in Healthy Male and Female Subjects Following a Single, Oral Dose of the Assigned Formulation of Nebivolol Tablets Under Fasting Conditions ............................................................... 293
Table 142. Mean (%CV) l-Nebivolol Pharmacokinetic Parameters in Healthy Male and Female Subjects Following a Single, Oral Dose of the Assigned Formulation of Nebivolol Tablets Under Fasting Conditions .......................................................... 294
Table 143. Mean (%CV) d,l-Nebivolol Pharmacokinetic Parameters in Healthy Male and Female Subjects Following a Single, Oral Dose of the Assigned Formulation of Nebivolol Tablets Under Fasting Conditions .............................................................. 294
Table 144. Mean (%CV) nebivolol Glucuronides Pharmacokinetic Parameters in Healthy Male and Female Subjects Following a Single, Oral Dose of the Assigned Formulation of Nebivolol Tablets Under Fasting Conditions (NEBI-0126) ................................................................................................................................. 295
Table 145. Summary of DBP, SBP, HR, and QTC for EMs and PMs at Screening and Exit (NEBI-0126) .......... 295
Table of Figures

Figure 1. Nitric Oxide Release from Endothelial Cells Following Acute Treatment with Nebivolol and Its Enantiomers .......................................................... 54
Figure 2. Nitric Oxide Release Following Acute Treatment with Nebivolol, Bucindolol, Metoprolol, and Carvedilol ................................................................. 55
Figure 3. Nitric Oxide Releasing Effect of Various Beta-Blockers on Human Endothelial Cells ......................................................................................... 55
Figure 4. Nebivolol and its Enantiomers Partition to a Similar Membrane Location .......................................................... 56
Figure 5. Predicted Location of Nebivolol, Metoprolol, Carvedilol, and Atenolol in Cell Membrane .......................................................... 57
Figure 6. Peak NO Release Following Acute Treatment with Nebivolol Metabolites (10μM) .......................................................... 58
Figure 7. Peak NO Release Following Treatment with Acetylcholine, Nebivolol, and Nebivolol Metabolites (5μM Treatment) .......................................................... 58
Figure 8. Effects of Nebivolol and Metabolites on Peak NO Release from Human Endothelial Cells Following Acute Treatment (50 μM) .......................................................... 60
Figure 9. Effects of Nebivolol and Nebivolol Metabolites on Peak NO Release from Human Endothelial Cells Following Acute Treatment (50 μM) .......................................................... 60
Figure 10. Peak NO Release in Endothelial Cells after Chronic Treatment with Nebivolol or Atenolol (10 μM) Followed by Stimulation with Calcium Ionophore (1 μM) .............................................................................. 61
Figure 11. Comparison of Acetylcholine (1 μM) Stimulated NO Release from Caucasian and Black Donor Endothelial Cells .............................................................................. 62
Figure 12. Release of NO after Chronic Treatment with β1-Adrenoceptor Blockers (10 μM) Followed by Stimulation with Acetylcholine (1 μM) .......................................................... 63
Figure 13. Effects of Acute Treatment with Nebivolol, Ramiprilat, and Enalapril on Peak Nitric Oxide Release from Human Endothelial Cells .............................................................................. 65
Figure 14. Separate and Combined Effects of Acute Treatment with Nebivolol and ACE Inhibitors on Peak NO Release from Human Endothelial Cells .............................................................................. 65
Figure 15. Effects of Nebivolol and Its Enantiomers (1, 10, and 100 μM) on NO Release from Endothelium-Intact WKY Rats .............................................................................. 66
Figure 16. Effects of Nebivolol and Its Enantiomers (10 μM) on NO Release from Arteries of WKY and SHR Rats .............................................................................. 67
Figure 17. Effects of Nebivolol (10 M), Nebivolol Enantiomers (10 μM), and Acetylcholine (1 μM) on NO Release from Endothelium-Intact Rat Arteries .............................................................................. 67
Figure 18. Effects of Calcium Ionophore and Acetylcholine (1 μM) on NO Release from Endothelium-Intact Rat Arteries .............................................................................. 68
Figure 19. Exercise Heart Rate .............................................................................. 75
Figure 20. Forearm Blood Flow with Nebivolol Isomers (GBR-29) (Mean +/− SE) .............................................................................. 80
Figure 21. Effect of Nebivolol on Forearm Blood Flow (GBR-23) (Mean ± SEM) .............................................................................. 81
Figure 22. Efficacy Findings (GBR-25) .............................................................................. 82
Figure 23. Effect of L-Arginine and L-NMMA on Responses to Nebivolol During Visit 2 (GBR-28) .............................................................................. 84
Figure 24. Effect of Atenolol on Forearm Blood Flow (Mean ± SE) (GBR-27) .............................................................................. 85
Figure 25. Effect of Nebivolol on Forearm Blood Flow (Mean ± SE) (GBR-27) .............................................................................. 86
Figure 26. Saline Control (C) and Blood Flow During Isoprenaline (GBR-27) .............................................................................. 86
Figure 27. Mean Haemodynamic Data (± SEM) Before Nebivolol and After the Intravenous and Oral Application of the Drug (LMD No. 59987) ................................................................. 100

Figure 28. Individual Changes in Haemodynamics After Intravenous and Oral Application of Nebivolol (LMD No. 59987) ......................................................................................... 101

Figure 29. Mean Values (± SEM) of Heart Rate and Blood Pressure 6 Hours After a Single Oral Intake of Placebo, 10 mg, and 20 mg of Nebivolol in 12 Healthy Volunteers in a Randomized Cross-Over Study (BEL-19) ......................................................................................... 103

Figure 30. Mean Values (± SEM) of Systolic Time Intervals 6 Hours After a Single Oral Intake of Placebo, 10 mg and 20 mg of Nebivolol in 12 Healthy Volunteers in a Randomized Cross-Over Study (BEL-19) ......................................................................................... 104

Figure 31. Mean Values (± SEM) of ECG-Intervals 6 Hours After a Single Oral Intake of Placebo, 10 mg and 20 mg of Nebivolol in 12 Healthy Volunteers in a Randomized Cross-Over Study (QTc = Bazett's Correction) (BEL-19) ......................................................................................... 105

Figure 32. Effect of a 1-Week Double-Blind Placebo-Controlled Cross-Over Treatment with Nebivolol 5 mg O.D. on Systolic Time Intervals in 10 Healthy Volunteers ........................................................................... 107

Figure 33. P2c Before, During, and After a 7-Day Treatment with dl-Nebivolol 5 mg O.D., d-Nebivolol 2.5 mg O.D., d-Nebivolol 2.5 mg O.D., and Atenolol 100 mg O.D. in 7 Healthy Volunteers (BEL-32) ......................................................................................... 108

Figure 34. PEPc Before, During, and After a 7-Day Treatment with dl-Nebivolol 5 mg O.D., d-Nebivolol 2.5 mg O.D., d-Nebivolol 2.5 mg O.D. and Atenolol 100 mg O.D. in 7 Healthy Volunteers (BEL-32) ......................................................................................... 109

Figure 35. PEPc/LVETc Ratio Before, During, and After a 7-Day Treatment with dl-Nebivolol 5 mg o.d., l-Nebivolol 2.5 mg O.D., d-Nebivolol 2.5 mg O.D., and Atenolol 100 mg O.D. in 7 Healthy Volunteers (BEL-32) ......................................................................................... 110

Figure 36. Haemodynamic Effects of Nebivolol in Hypertensive Patients (Dye Dilution Technique, 2 x 4 Weeks Cross-Over with Placebo) (n = 9) (NED-7) ........................................................................... 120

Figure 37. Mean Exercise-Related SBP on a Control Day and at 3 Hours Post Dosing (BEL-30) ................................................................................................................................. 123

Figure 38. Mean Exercise-Related SBP on a Control Day and at 6 Hours Post-Dosing (BEL-30) ................................................................................................................................. 124

Figure 39. Mean Exercise-Related Heart Rate on a Control Day and at 3 Hours Post-Dosing (BEL-30) ................................................................................................................................. 125

Figure 40. Mean Exercise-Related Heart Rate on a Control Day and at 6 Hours Post-Dosing (BEL-30) ................................................................................................................................. 125

Figure 41. Rate-Pressure Product on a Control Day and at 3 Hours Post-Dosing (BEL-30) ................................................................................................................................. 126

Figure 42. Resting SBP During a Control Day and 0, 3, and 6 Hours Post-Nebivolol Dosing (BEL-30) ................................................................................................................................. 126

Figure 43. Resting DBP During a Control Day and 0, 3, and 6 Hours Post-Nebivolol Dosing (BEL-30) ................................................................................................................................. 127

Figure 44. Resting Mean Arterial Pressure During a Control Day and at 0, 3, and 6 Hours Post- Nebivolol Dosing (BEL-30) ................................................................................................................................. 127

Figure 45. Heart Rate Measured Before Drug Intake on a Control Day and on the 7th and 14th Day of Dosing. (Source: Table 5, BEL-1/Part II) ................................................................................................................................. 130

Figure 46. Blood Pressure Results, Measured Before Drug Intake on a Control Day and on the 7th and 14th Day of Drug Intake (Source: Table 5) (BEL-1/Part II) ................................................................................................................................. 130
Figure 47. Mean Heart Rate Before, During and After Exercise Testing on Day 14 (BEL-1/Part II) ........................................................................................................................................ 131
Figure 48. Mean Systolic BP Before, During, and After Exercise Testing on Day 14 (BEL-1/Part II) ........................................................................................................................................ 131
Figure 49. Mean Systolic BP Before, During, and After Exercise Testing on Day 7 (BEL-1/Part II) ........................................................................................................................................ 132
Figure 50. Exercise-Related Heart Rates (3 Hours after Dosing) (Study ID N/A) ........................................................................................................................................ 134
Figure 51. Exercise-Related Heart Rates (6 Hours After Dosing) (Study ID: N/A) ........................................................................................................................................ 135
Figure 52. Exercise-Related SBP (mm Hg) 3 Hours After Dosing (Study ID: N/A) ........................................................................................................................................ 135
Figure 53. Exercise-Related SBP (mm Hg) 6 Hours After Dosing (Study ID: N/A) ........................................................................................................................................ 136
Figure 54. Mean HR (bpm), BP (mm Hg), and Systolic Time Intervals (msec) Before and Up to 6 Hours After IV Administration of Nebivolol 0.5 mg ........................................................................................................................................ 137
Figure 55. Mean Exercise-Induced Increase in HR and SBP 6 Hours Post-Dosing ........................................................................................................................................ 139
Figure 56. Mean HR and SBP at Maximal Exercise (9 minutes) Measured 6 Hours Post Dosing ........................................................................................................................................ 139
Figure 57. Mean Resting HR and SBP (Pre-Dose) ........................................................................................................................................ 140
Figure 58. Resting Supine BP and HR (BEL-38) ........................................................................................................................................ 141
Figure 59. Resting PEPc/LVETc ........................................................................................................................................ 142
Figure 60. Exercise-Related Change in HR, SBP, and LVETc-Shortening ........................................................................................................................................ 142
Figure 61. Heart Rate (Upper Panel) and SBP (Lower Panel) Before, During, and After Exercise Testing on a Control day (....) and On Day 7 (______) of a Subacute Treatment with d-Nebivolol 5 mg Daily, l-Nebivolol 5 mg Daily, and dl-Nebivolol 10 mg Daily in 7 Healthy Volunteers (BEL-36) ........................................................................................................................................ 144
Figure 62. Mean Values (±SE) of PEPc/LVETc Ratio (Upper Panel) and ΔLVETc Post-Pre Exercise Testing (Lower Panel) on a Control Day (C) and Regularly During and After a 7-Day Treatment with d-Nebivolol 5 mg/day, l-Nebivolol 5 mg/day, and dl-Nebivolol 10 mg/day in 7 Healthy Volunteers (BEL-36) ........................................................................................................................................ 145
Figure 63. Mean Resting Heart Rate (HR) and Blood Pressure (BP) by Treatment (CTRL = Control; 1, 2.5, 5, and 10 Refer to mg Nebivolol Dose Groups) (RSA-1) ........................................................................................................................................ 146
Figure 64. HandgripTest Before (----) and After (______) a 14-Day Treatment with Atenolol or Nebivolol in 14 Volunteers (BEL-9) ........................................................................................................................................ 149
Figure 65. Increase of Heart Rate and Blood Pressure During a HandgripTest on a Control Day (C) and After a 14-Day Treatment with Atenolol 100 mg O.D. (A) or Nebivolol 5 mg O.D. (N). (BEL-9) ........................................................................................................................................ 150
Figure 66. Simultaneous Registration of Phonocardiogram, Carotid Pulse Wave, and Electrocardiogram ........................................................................................................................................ 151
Figure 67. Mean Values ±SE of the Ratio PEPC/LVETc During a 7-Day Treatment and After Discontinuation of Treatment with Atenolol 100 mg O.D., Propranolol 160 mg O.D., Pindolol 5 mg T.I.D. and Nebivolol 5 mg O.D. in 7 Volunteers ........................................................................................................................................ 153
Figure 68. Mean Values ±SE of the ΔLVETc Pre-Post Exercise During a 7-Day Treatment and After Discontinuation of Treatment with Atenolol 100 mg O.D., Propranolol 160 mg O.D., Pindolol 5 mg T.I.D. and Nebivolol 5 mg O.D. in 7 Volunteers ........................................................................................................................................ 154
Figure 69. Mean Values ±SE of the Ratio PEPC/LVETc During a 7-Day Treatment and After Discontinuation of Treatment with d-Nebivolol 5 mg O.D., l-Nebivolol 5 mg O.D. and dl-Nebivolol 10 mg O.D. in 7 Volunteers ........................................................................................................................................ 155
Figure 70. Mean Values ±SE of the ΔLVETc Pre-Post Exercise During a 7-Day Treatment and After Discontinuation of Treatment with d-Nebivolol 5 mg O.D., l-Nebivolol 5 mg O.D., and dl-Nebivolol 10 mg O.D. in 7 Volunteers .......................................................... 156
Figure 71. A: Percentage Decrease in Exercise-Induced Tachycardia (n = 11) B: Mean Reduction in Mean Arterial Pressure at Rest (n = 11) (NED-11) ........................................... 159
Figure 72. Isoprenaline Induced Tachycardia: CD20 Ratio (n = 11) (NED-11) .......................... 159
Figure 73. Phenylephrine Dose-Response Test (n = 9) (NED-11) ........................................ 160
Figure 74. Heart Rate and Systolic Blood Pressure at Maximal Exercise and 1 Min After the End of Exercise After a Single Oral Intake of 2.5 mg of d-Nebivolol, 2.5 mg of l-Nebivolol, and 5 mg of dl-Nebivolol in a Double-Blind Placebo-Controlled Study in 10 Healthy Volunteers (BEL-15) ......................................................... 161
Figure 75. Mean Rest Values of Systolic Time Intervals After a Single Oral Intake of 2.5 mg of d-Nebivolol (d), 2.5 mg of l-Nebivolol (l), and 5 mg of dl-Nebivolol (dl) in a Double-Blind Placebo (P)-Controlled Study in 10 Healthy Volunteers (BEL-15) ......................................................... 162
Figure 76. Shortening of LVETc After Exercise, After a Single Oral Intake of 2.5 mg of d-Nebivolol (d), 2.5 mg of l-Nebivolol (l), and 5 mg of dl-Nebivolol (dl) in a Double-Blind Placebo (P)-Controlled Study in 10 Healthy Volunteers (BEL-15) ......................................................... 163
Figure 77. Nebivolol Dose Response: Heart Rate Over 3 Week Period .................................. 165
Figure 78. Nebivolol Dose Response: Systolic BP Over 3 Week Period ................................. 166
Figure 79. Heart Rate During Exercise (SWE-1) .................................................................... 170
Figure 80. Systolic Blood Pressure During Exercise (SWE-1) .............................................. 171
Figure 81. Exercise Heart Rate (GBR-19) ........................................................................... 173
Figure 82. Exercise Cardiac Index (GBR-19) ....................................................................... 173
Figure 83. Mean Values of LVETc Post-Pre Exercise on a Control Day (C) and on Day 7 or 14 of a Subacute Treatment Period with Nebivolol 5 or 10 mg/day (N) in 14 Normal and 7 Poor Metabolizers .......................................................... 185
Figure 84. Effects on Heart Rate and Systolic Blood Pressure 1 Minute after Exercise, Before, During, and After Discontinuation of An 8-Day Treatment with Nebivolol in 6 Poor and 6 Normal Metabolizers (BEL-4/Part I) ......................................................... 189
Figure 85. Exercise-Induced Shortening of LVETc Before, During, and After Discontinuation of an 8-Day Treatment with Nebivolol in 6 Poor and 6 Normal Metabolizers (BEL-4/Part I) ......................................................... 190
Figure 86. Individual and Mean Values of QTc- and QTm-Intervals and QT/QS; Ratio Before, During, and After a 8-Day Intake of Nebivolol in 6 Poor and 6 Normal Metabolizers (BEL-4/Part II) ........................................................................... 191
Figure 87. Graphical presentation: Individual and Mean Serum Hormonal Levels (Basal and After ACTH Stimulation) (BEL-55) ..................................................................... 206
Figure 88. Trial Design (CAN-8) ......................................................................................... 221
Figure 89. Glucose/Insulin Homeostasis - Plasma Insulin Levels During IVGTT (CAN-8) .... 224
Figure 90. Ambulatory Systolic Blood Pressure Over 24-Hours (CAN-8) ............................. 226
Figure 91. Ambulatory Diastolic Blood Pressure Over 24-Hours (CAN-8) ........................... 227
Figure 92. Ambulatory Heart Rate Over 24-Hours (CAN-8) ................................................. 228
Figure 93. Linear Mean Plasma Concentration-Time Plot after Single Oral Intake of 5 mg Nebivolol Alone or in Combination with 0.23 g/kg Alcohol in 14 Extensive Metabolizers (Upper Graph) and Two Poor Metabolizers (Lower Graph) (GBR-14) ......................................................... 241
Figure 94. Linear Mean Plasma Concentration-Time Plot after Single Oral Intake of 5 mg Nebivolol Alone or in Combination with 0.23 g/kg Alcohol Given to Fourteen Extensive Metabolizers (Upper Graph) and Two Poor Metabolizers (Lower Graph) (GBR-14) .... 242

Figure 95. Linear Mean Plasma Concentration-Time Plot after Single Oral Intake of 5 mg Nebivolol Alone or in Combination with 0.23 g/kg Alcohol Given to Fourteen Extensive Metabolizers (Upper Graph) and Two Poor Metabolizers (Lower Graph) .............. 243

Figure 96. Blood Levels of Alcohol Over Time (GBR-14) .................................................. 244

Figure 97. Dose Response Curves of SGaw (GBR-22) ......................................................... 248

Figure 98. Effect of Nebivolol on Specific Airways Conductance (n = 6) ................................ 249

Figure 99. Forced Expiratory Volume in 1 Second (Baseline, Post-Treatment, and After Salbutamol) (GBR-22) ........................................................................................................ 250

Figure 100. Plasma Renin Activity and Serum Aldosterone at 2 and 4 Weeks of Treatment... 255

Figure 101. Graphical Presentation of Heart Rate (HR) (IT-2) .................................................. 256

Figure 102. Change in Intraocular Pressure in Healthy Volunteers with R67555 0.25% Eye Drops ........................................................................................................................................... 258

Figure 103. Change in Intraocular Pressure in Healthy Volunteers with Timolol 0.25% Eye Drops ........................................................................................................................................... 259

Figure 104. Effects of .25% R67555 and .25% Timolol as compared with .1% R67555 .... 260

Figure 105. SBP and DBP in Healthy Volunteers after R67555 and Timolol Eye Drops ....... 261

Figure 106. Heart Rate in Healthy Volunteers after R67555 and Timolol Eye Drops ......... 262

Figure 107. Difference in IOP Between Treated and Untreated Eyes .................................. 264

Figure 108. Difference in IOP Between Treated and Untreated Eyes ................................. 265

Figure 109. Blood pressure During Treatment with R67555 Eye Drops or Solvent .......... 266

Figure 110. Heart Rate During Treatment with R67555 Eye Drops or Solvent ................. 267

Figure 111. Heart Rate During Treatment with 0.25% Timolol Eye Drops ....................... 268

Figure 112. Main Features of the Trial Sample and Summary of the Results. Summary of Therapeutic Results (BEL-3/6) ........................................................................................................... 286

Figure 113. Summary of Safety Results (BEL-3/6) ................................................................ 287

Appears This Way
On Original
1 REVIEW OF INDIVIDUAL SUPPORTIVE STUDIES

The Agency reviewed all supportive studies submitted by the sponsor. None of these studies altered the efficacy results of the Pivotal studies. Table 1 and Table 2 provide a list of the supportive studies. The reviews for the individual studies may be found either within the Tables or in the section following Table 1 and Table 2. The number prior to the study title corresponds to # in the Table.

The reviews were performed as follows:

- Dr. Maryann Gordon reviewed Studies #25 through #30 and #70 through #93.
- Dr. Karen A. Hicks reviewed Studies #1 through #24, #39, #40, #41, #43, #44, #46 through #69, and #134 through #151.
- Dr. Katharine R. Lillie reviewed Studies #73 and #76.
- Dr. Juan Carlos Pelayo reviewed Studies #94 through #133.
- Dr. Shari Targum reviewed Studies #31 through #38, #42, and #45.
<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Study Category/ Type/Design</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>N/A</td>
<td>1270_01_00</td>
<td>Comparative Effects of Nebivolol, Nebivolol Enantiomers, Atenolol, Metoprolol, Carvedilol and Bacindolol on Human Endothelial Cell Nitric Oxide Release Following Acute Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>2</td>
<td>N/A</td>
<td>1273_01_00</td>
<td>Comparative Effects of Nebivolol, Nebivolol Enantiomers, and Six Nebivolol Metabolites on Endothelial Nitric oxide Release from Human Endothelial Cells following Acute Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>3</td>
<td>N/A</td>
<td>1332_01_00</td>
<td>Comparative Effects of Nebivolol Metabolites 4,5'-dihydroxy, 4,8'-dihydroxy, Glucuronide, Nebivolol and Nebivolol Enantiomers on Endothelial Cells following Acute Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>4</td>
<td>N/A</td>
<td>1333_00_00</td>
<td>Comparative Effects of Nebivolol and Atenolol on Nitric Oxide Release from Human Endothelial Cells following Chronic Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>5</td>
<td>N/A</td>
<td>1334_00_00</td>
<td>Comparative Effects of Nebivolol and Atenolol on Nitric Oxide Release in Black and Caucasian Endothelial Cells following Chronic Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>6</td>
<td>N/A</td>
<td>1271_01_00</td>
<td>Effects of Nebivolol and ACE-Inhibitors on Endothelial Nitric Oxide Release in Black and Caucasian Donor Endothelial Cells following Chronic Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>7</td>
<td>N/A</td>
<td>1269_01_00</td>
<td>Separate and Combined Effects of Nebivolol and ACE-Inhibitors on Human Endothelial Cell Nitric Oxide Release following Chronic Treatment</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>8</td>
<td>N/A</td>
<td>1268_01_00</td>
<td>Effects of Acute Nebivolol Treatment on Nitric Oxide Release and Vascular Function in Normal versus Diseased Mesenteric Arteries</td>
<td>Molecular pharmacology, Nitric oxide effects, In vitro</td>
</tr>
<tr>
<td>9</td>
<td>N/A</td>
<td>1312_01_00</td>
<td>Adrenergic Receptor Pharmacology of Nebivolol in the Human Heart</td>
<td>Molecular Pharmacology, Beta adrenergic receptor affinity, In vitro</td>
</tr>
<tr>
<td>10</td>
<td>N/A</td>
<td>1311_01_00</td>
<td>Adrenergic Receptor Pharmacology of Nebivolol, its Enantiomers and Nine Metabolites in the Human heart</td>
<td>Molecular pharmacology, Beta adrenergic receptor affinity, In vitro</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>--------</td>
<td>---------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>92890</td>
<td></td>
<td>A Comparative Study of the Relative Beta-Blocking Potency, and Beta-1 selectivity of Nebivolol, Propranolol and Atenolol in Healthy Volunteers.</td>
<td></td>
</tr>
<tr>
<td>14</td>
<td>108078</td>
<td>BEL-20</td>
<td>Determination of the Acute and Subacute Beta-Sympatholytic Activity of d-, l-, and dl Nebivolol compared to Atenolol and Placebo, in Inhibiting Exercise-Induced Tachycardia. Synoptic Clinical Research Report NEB-BEL-20, April 1994</td>
<td>Pharmacodynamics, Beta blockade, Double-blind, placebo-controlled</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>23</td>
<td>N/A</td>
<td>49278</td>
<td>Effect of a Single Oral Intake of R67555 (5 mg and 10 mg) and of a 7-Day Intake of R67555 (5 mg/day) on ECG. Clinical Research Report. February 1986.</td>
<td>Pharmacodynamic, Hemodynamic, Open-label, cross-over</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>-----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>106560</td>
<td></td>
<td>Invasive Hemodynamics of Nebivolol in Hypertensive Patients.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>45715</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>34</td>
<td>59580</td>
<td>N/A</td>
<td>Randomized Cross-Over Study Comparing the Haemodynamic Effects during Exercise of a Single Administration of Nebivolol 0.5 mg I.V., 5 mg Tablet and 5 mg Solution in Healthy Volunteers. Clinical Research Report. March 1987.</td>
<td>Pharmacodynamic, Hemodynamic, Open-label, placebo-controlled, cross-over</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
</tr>
<tr>
<td>-----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>38</td>
<td>64858</td>
<td>RSA-1</td>
<td>The Effects of Nebivolol on Heart Rate and Blood Pressure at Rest and During Exercise. A Dose Finding Study. Clinical Research Report NEB-RSA-1.</td>
<td>Pharmacodynamic, Hemodynamic, Open-label, cross-over</td>
</tr>
<tr>
<td>40</td>
<td>106561</td>
<td>NED-11</td>
<td>Pharmacological Properties of Nebivolol in Man</td>
<td>Hemodynamic, Single-blind, cross-over</td>
</tr>
<tr>
<td>42</td>
<td>68099</td>
<td>RSA-5</td>
<td>The Effects of Nebivolol on Heart Rate and Blood Pressure at Rest and During Exercise. A Sub-Acute Dose Finding Study. Clinical Research Report NEB-RSA-5.</td>
<td>Pharmacodynamic, Hemodynamic, Double-blind, placebo-controlled, parallel groups</td>
</tr>
<tr>
<td>44</td>
<td>88260</td>
<td>GBR-19</td>
<td>The Effect of Nebivolol on Heart Rate, Blood Pressure and Cardiac Output at Rest and During Exercise in Healthy Volunteers. February 1991.</td>
<td>Pharmacodynamic, Hemodynamic, Double-blind, placebo-controlled</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/ Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>49</td>
<td>92970</td>
<td>INT-2</td>
<td>Effect of Nebivolol (5 mg) on Exercise Induced Tiredness in Essential Hypertension. A Double-Blind, Randomized Comparison with Atenolol (50 mg) and Placebo, After a 4-week Placebo Run-In Period. Clinical Research Report NEB-INT-2. August 1993.</td>
<td>Pharmacodynamic, Hemodynamic, Double-blind, placebo-controlled, active-controlled, cross-over</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>62</td>
<td>92864</td>
<td>N/A</td>
<td>A Study to Assess the Effects of Nebivolol on Sedation and Psychomotor Performance.</td>
<td>Pharmacodynamic, Psychomotor/sedation, Double-blind, placebo-controlled, cross-over</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>---------------------------</td>
</tr>
<tr>
<td>66</td>
<td>49643</td>
<td>N/A</td>
<td>Randomized Double-Blind Cross-Over Study of the Effects of Topical R67555 as Compared with Timolol on the Intraocular Pressure, Blood Pressure and Heart Rate in Human Healthy Volunteers. April 1986.</td>
<td>Pharmacodynamic, Ophthalmic, Double-blind, active-controlled, cross-over</td>
</tr>
<tr>
<td>67</td>
<td>51686</td>
<td>N/A</td>
<td>Randomized Double-Blind Cross-Over Study of the Effects of Topical R67555 as Compared with R67555 Solvent and Timolol, on the Intraocular Pressure, Blood Pressure and Heart Rate in Human Healthy Volunteers. July 1986</td>
<td>Pharmacodynamic, Ophthalmic, Double-blind, active-controlled, cross-over</td>
</tr>
<tr>
<td>68</td>
<td>46816</td>
<td>N/A</td>
<td>Safety Data after Oral Administration of R65824 5 mg/day for 7 Consecutive Days in 6 Human Volunteers. December 1985.</td>
<td>Pharmacodynamic, Safety, Open-label</td>
</tr>
<tr>
<td>69</td>
<td>46817</td>
<td>N/A</td>
<td>Safety Data After a Single Oral Administration of 5 mg and 10 mg of R65824 in 8 Human Volunteers. December 1985.</td>
<td>Pharmacodynamic, Safety, Open-label</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/Design</td>
</tr>
<tr>
<td>---</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------</td>
</tr>
</tbody>
</table>
| 70 | 88035   | INT-1 US Study Results | Report of U.S. Study Results in an International Trial: Nebivolol in the Treatment of Essential Hypertension (A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study). Clinical Research Report NEB-INT-1. March 1992. | Janssen, Hypertension Double-blind, Placebo-controlled, Parallel groups | Sample size/Mean change from baseline at endpoint intent-to-treat (supine or sitting DBP at trough mm Hg)*<br>Placebo: 42/ -3.0<br>0.5 mg: 42/-5.4<br>1 mg: 42/-4.7<br>2.5 mg: 43/-5.5<br>5 mg: 44/-9.1<br>10 mg: 41/-8.7 |}
| 71 | 101220  | INT-1 Non-US | The Effect of Nebivolol (0.5, 1, 2.5, 5, and 10 mg) in the Treatment of Essential Hypertension. A Double-Blind, Randomized Comparison with Placebo in an International Dose-Finding Trial. Clinical Research Report NEB-INT-1. March 1992. | Janssen, Hypertension Double-blind, Placebo-controlled, Parallel groups | Placebo: 84/-3.3<br>0.5 mg: 83/-4.0<br>1 mg: 87/-6.0<br>2.5 mg: 85/-7.1<br>5 mg: 86/-9.2<br>10 mg: 84/-10.1 |}
| 72 | 106572  | USA-1     | Comparison of Antihypertensive and Beta-1-Adrenoceptor Antagonist Effect of Nebivolol and Atenolol in Essential Hypertension. (Clinical and Experimental Hypertension; 15(3): 501-509, 1993). | Janssen, Hypertension Double-blind, Placebo-controlled, Parallel group, Active-controlled, Cross-over | 1. Diastolic and systolic blood pressures were reduced to the same extent by nebivolol and atenolol;<br>2. PEP/LVET as an indirect measure for left ventricular performance shows a favorable decrease in the nebivolol 10 mg group compared to the unchanged value after atenolol. |}
<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Disease State/Design</th>
<th>Efficacy Results*</th>
</tr>
</thead>
<tbody>
<tr>
<td>75</td>
<td>106916</td>
<td>USA-6</td>
<td>Nebivolol in Congestive Heart Failure: a Placebo-Controlled, Double-Blind, Dose-Titration, Pilot Study. Clinical Research Report NEB-USA-4. November 1994.</td>
<td>Janssen, Other cardiovascular condition Double-blind, Placebo-controlled, Parallel groups</td>
<td>Placebo: 19 Nebivolol: 19 6-Minute Walk Test At the overall endpoint, the walking distance for subjects on placebo was significantly increased compared to baseline (p ≤ 0.04), whereas there was no significant increase in subjects on nebivolol.</td>
</tr>
<tr>
<td>77</td>
<td>101219</td>
<td>BEL-12/18</td>
<td>The Effect of Nebivolol (0.5, 1, 2.5 and 5 mg) in the Treatment of Essential Hypertension. A Double-Blind, Randomized Comparison with Placebo in a Dose Finding Trial Followed by an Open Long-Term Follow-Up. Clinical Research Report NEB-BEL-12/18. June 1994.</td>
<td>Janssen, Hypertension Double-blind, Placebo-controlled, Parallel groups, Open-label</td>
<td>Placebo: 41/-9.4 0.5 mg: 37/-12.5 1 mg: 41/-10.6 2.5 mg: 42/-17.0 5 mg: 42/-14.4</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/Design</td>
<td>Efficacy Results*</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------</td>
<td>--------------------------------------------------------</td>
</tr>
</tbody>
</table>
<pre><code>                                                                                                                            |                                                           | 10 mg Enalapril: 205/-9.8                             |
</code></pre>
                                                                                                                                |                                                           | d1 nebivolol: -11.8  
                                                                                                                                |                                                           |  
                                                                                                                                |                                                           | d nebivolol: -11.5  
                                                                                                                                |                                                           |  
                                                                                                                                |                                                           | Atenolol: -11.5  
                                                                                                                                |                                                           |  
                                                                                                                                |                                                           | 1 nebivolol: -2.1  
                                                                                                                                |                                                           |  
                                                                                                                                |                                                           | Placebo: -4.3                                              |
                                                                                                                                |                                                           | Enalapril: 32/-0.3                                      |
                                                                                                                                |                                                           | Nifedipine: 90/0.3                                      |
                                                                                                                                |                                                           | Nifedipine: 85/-10.6                                     |
                                                                                                                                |                                                           | Left ventricular mass index, g/m²:  
                                                                                                                                |                                                           | Mean at Baseline/endpoint  
                                                                                                                                |                                                           | Nebivolol: 162.7/147.3  
                                                                                                                                |                                                           | (n=24*)  
                                                                                                                                |                                                           |  
                                                                                                                                |                                                           | Atenolol: 168.0/149.9  
                                                                                                                                |                                                           | (n=24*)  
<p>| |
|                                                           |<br />
|                                                           | * End systolic values for secondary echocardiography parameters were available in only half of the patients |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Disease State/Design</th>
<th>Efficacy Results*</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Therapeutic results</th>
<th>Double-blind phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>(n = number of patients with efficacy data)</td>
<td>nebulivelol (n=82)</td>
</tr>
<tr>
<td>Primary parameters</td>
<td>102.6/85.3*</td>
</tr>
</tbody>
</table>

(Reproduced from Sponsor, Study ID TCH 1/2, page 8)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Nebivolol: 30 (99/91)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>d-nebivolol: 30 (99/90)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hormones (renin, progesterone, testosterone, ACTH, aldosterone, cortisol, LH, FSH, estradiol): no clinically significant between treatment changes. Significant decrease from baseline in plasma renin concentration following nebivolol and d-nebivolol.</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/ Design</td>
<td>Efficacy Results*</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
</tr>
</tbody>
</table>

### Pharmacodynamic and Clinical Results

<table>
<thead>
<tr>
<th>Parameter</th>
<th>End of run-in</th>
<th>Nebivolol (n=21)</th>
<th>Atenolol (n=20)</th>
<th>Placebo (n=21)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maximum venous outflow, ml/min/100 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>arm pre-nitro</td>
<td>41.2±1.63</td>
<td>39.9±1.77</td>
<td>42.1±2.08</td>
<td>40.4±2.01</td>
</tr>
<tr>
<td>arm post-nitro</td>
<td>5.7±0.80</td>
<td>4.6±0.99</td>
<td>5.7±0.81</td>
<td>6.3±0.84</td>
</tr>
<tr>
<td>leg pre-nitro</td>
<td>40.7±2.23</td>
<td>39.2±1.90</td>
<td>41.0±1.81</td>
<td>40.1±2.33</td>
</tr>
<tr>
<td>leg post-nitro</td>
<td>6.6±0.82</td>
<td>4.9±0.99</td>
<td>6.2±0.81</td>
<td>6.0±0.55</td>
</tr>
<tr>
<td>Venous volume, ml/100 ml</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>arm pre-nitro</td>
<td>2.4±0.08</td>
<td>2.5±0.07</td>
<td>2.6±0.07</td>
<td>2.6±0.06</td>
</tr>
<tr>
<td>arm post-nitro</td>
<td>0.3±0.02</td>
<td>0.3±0.02</td>
<td>0.3±0.03</td>
<td>0.2±0.03</td>
</tr>
<tr>
<td>leg pre-nitro</td>
<td>2.6±0.14</td>
<td>2.8±0.12</td>
<td>2.7±0.10</td>
<td>2.7±0.08</td>
</tr>
<tr>
<td>leg post-nitro</td>
<td>0.1±0.05</td>
<td>0.2±0.06</td>
<td>0.2±0.05</td>
<td>0.2±0.02</td>
</tr>
</tbody>
</table>

(Reproduced from Sponsor, Study ID RSA-6, page 2)


Appears This Way
On Original

32
<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Disease State/Design</th>
<th>Efficacy Results*</th>
</tr>
</thead>
</table>

*Display 5c: Mean Difference from Baseline Scores for Trough Sitting Diastolic Blood Pressure (mmHg) - Week 4

(Reproduced from Sponsor, Study ID CAN-6, Display 5c, page 62)

<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Disease State/Design</th>
<th>Efficacy Results*</th>
</tr>
</thead>
<tbody>
<tr>
<td>93</td>
<td>107415</td>
<td>CAN-6</td>
<td>Clinical Evaluation of the Antihypertensive Efficacy and Safety of Nebivolol versus Lisinopril in Patients with Confirmed Mild to Moderate Essential Hypertension. Clinical Research Report NEB-CAN-6. July 1994.</td>
<td>Janssen, Hypertension Double-blind, Active-controlled, Cross-over</td>
<td>(Clinic BP: A responder is defined as patients having a sitting DBP &lt; 90 mm Hg or decrease ≥ 10 mm Hg) % Responders: Lisinopril: 29/52% Nebivolol 29/41%</td>
</tr>
</tbody>
</table>

Appears This Way
On Original

33
<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Disease State/Design</th>
<th>Efficacy Results*</th>
</tr>
</thead>
<tbody>
<tr>
<td>95</td>
<td>109042</td>
<td>BEL-23</td>
<td>Tolerability of Nebivolol in Patients with Essential Hypertension. Synoptic Clinical Research Report NEB-BEL-23. November 1994.</td>
<td>Hypertension Open-label, Dose-escalation</td>
<td>Week 1: 22/10 mg; Week 2: 22/15 mg; Week 3-6: 22/20 mg. No DBP results, dosage-dependent AEs</td>
</tr>
<tr>
<td>97</td>
<td>108083</td>
<td>NED-4</td>
<td>Efficacy, Pharmacodynamics, Pharmacokinetics and Safety of Open Nebivolol Treatment (2.5 mg and 7.5 mg) in Hypertensive patients. Synoptic Clinical Research Report NEB-NED-4. December 1993.</td>
<td>Hypertension Open-label</td>
<td>2.5 mg: 6/-9.0 7.5 mg: 6/-16.0</td>
</tr>
<tr>
<td>98</td>
<td>109089</td>
<td>NED-9</td>
<td>Tolerability of Nebivolol in Patients with Essential Hypertension. Synoptic Clinical Research Report NEB-NED-9. November 1994.</td>
<td>Hypertension Open-label</td>
<td>Week 1: 10/10 mg; Week 2: 10/15 mg; Week 3-4: 10/20 mg. No DBP results, dosage-dependent AEs</td>
</tr>
<tr>
<td>99</td>
<td>84288</td>
<td>MEX-1</td>
<td>Long-Term Therapy with Nebivolol in Patients with Hypertension. (Drug Investigation; 3 (suppl. 1): 180-182, 1991).</td>
<td>Hypertension Open-label</td>
<td>5.0 mg (3 mos.): 40/-13.1 5.0 mg (6 mos.): 35/-15.2</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/Design</td>
<td>Efficacy Results*</td>
</tr>
<tr>
<td>-----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>102</td>
<td>109065</td>
<td>AUS-3</td>
<td>A Study to Establish the Acute Effects of Nebivolol on Blood Pressure and Whether or Not There are First Dose Postural Effects in Middle Aged and Elderly patients. Synoptic Clinical Research Report NEB-AUS-3. October 1994.</td>
<td>Hypertension Double-blind, Placebo-controlled, Active-controlled, Cross-over</td>
<td>(n=11) Efficacy data not reported</td>
</tr>
<tr>
<td>104</td>
<td>76693</td>
<td>ARG-1</td>
<td>Effects of Nebivolol on Left Ventricular Function in Patients with Essential Hypertension. (Drug Investigation; 3 (suppl. 1): 155-160, 1991).</td>
<td>Hypertension Double-blind, Active-controlled, Parallel groups</td>
<td>Nebivolol 5 mg: 15/-15.1 Atenolol 100 mg: 15/-11.4</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/Design</td>
<td>Efficacy Results*</td>
</tr>
<tr>
<td>----</td>
<td>----------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td></td>
<td>106927</td>
<td></td>
<td></td>
<td></td>
<td>Placebo: 14/-4.5  Nebivolol 5 mg: 14/-11.6</td>
</tr>
<tr>
<td>114</td>
<td>92596</td>
<td>RSA-8</td>
<td>Long-Term (3-month) Effects of A New Beta-Blocker (Nebivolol) on Cardiac Performance in Dilated Cardiomyopathy. (JACC; 21(5): 1094-1100, 1993)</td>
<td>Other cardiovascular condition, Double-blind, Placebo-controlled, Parallel groups</td>
<td>Placebo: 13/+1.0  Nebivolol 1-5 mg: 11/-6.0  Nebivolol + chronotropic &amp; -inotropic effect</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/Design</td>
<td>Efficacy Results*</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>116</td>
<td>101223</td>
<td>TCH-4</td>
<td>Clinical and Haemodynamic Effects of Nebivolol in Patients with Mild to Moderate Congestive Heart Failure. Clinical Research Report NEB-TCH-4. April 1994.</td>
<td>Other cardiovascular condition, Double-blind, Placebo-controlled, Parallel groups</td>
<td>Placebo: 29/+2.1 Nebivolol 2.5 mg: 29/-2.4 Nebivolol 5 mg: 33/-3.1</td>
</tr>
<tr>
<td>117</td>
<td>106563</td>
<td>BEL-42</td>
<td>Postoperative Haemodynamic Effects of Racemic Nebivolol Compared to d- and L-Nebivolol in Patients with Coronary Artery Bypass Grafting. Synoptic Clinical Research Report NEB-BEL-42. January 1994.</td>
<td>Other cardiovascular condition, Double-blind, Active-controlled, Parallel groups</td>
<td>Nebivolol-d 5 mg: 17/-1.3 Nebivolol-l 2.5 mg: 16/+1.8 Nebivolol-d 2.5 mg: 16/-0.2</td>
</tr>
<tr>
<td>119</td>
<td>84268</td>
<td>FRA-3</td>
<td>Pilot Study of Cardiovascular Effects of Nebivolol in Congestive Heart Failure. (Drug Investigation; 3 (suppl. 1): 69-81, 1991).</td>
<td>Other cardiovascular condition, Double-blind, Placebo-controlled, Parallel groups</td>
<td>Placebo: 6/+6 Nebivolol 1,2,5,5 mg: 6/-1</td>
</tr>
<tr>
<td>120</td>
<td>92860</td>
<td>GER-7</td>
<td>Determination of the Anti-Ischemic Activity of Nebivolol in Comparison with Atenolol. (International J. Cardiology; 43: 279-289, 1994).</td>
<td>Other cardiovascular condition, Double-blind, Active-controlled, Parallel groups</td>
<td>Nebivolol 5 mg: 12/? Atenolol 100 mg: 12/?</td>
</tr>
<tr>
<td>121</td>
<td>106920</td>
<td>TCH-3</td>
<td>Effect of Nebivolol and Metoprolol in Patients with Coronary Artery Disease and Depressed Left Ventricular Function. Synoptic Clinical Research Report NEB-TCH-3. October 1994.</td>
<td>Other cardiovascular condition, Double-blind, Parallel groups</td>
<td>Nebivolol 5 mg: 18/-4.8 Metoprolol 50 mg: 18/-4.8</td>
</tr>
<tr>
<td>122</td>
<td>79247</td>
<td>BEL-14</td>
<td>Comparison of Left Ventricular Haemodynamics of Nebivolol and Metoprolol in Patients with Acute Myocardial Infarction. (Drug Investigation; 3 (suppl. 1): 140-141, 1991).</td>
<td>Other cardiovascular condition, Double-blind, Active-controlled, Parallel groups</td>
<td>Nebivolol 5 mg: 40/-5.0 Metoprolol 100 mg: 40/-3.0</td>
</tr>
<tr>
<td>123</td>
<td>154909</td>
<td>NED-14</td>
<td>Nebivolol versus Atenolol in Postinfarction Patients with Left Ventricular Dysfunction. Analysis Tables and Graphs. June 1993.</td>
<td>Other cardiovascular condition, Active-controlled, Parallel groups</td>
<td>Nebivolol 5 mg: 13/-7.0 Atenolol 100 mg: 15/-8.0</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Disease State/Design</td>
<td>Efficacy Results*</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>124</td>
<td>92597</td>
<td>BEL-28</td>
<td>Administration of Nebivolol after Coronary Artery Bypass in Patients with Altered Left Ventricular Function. (J. Cardiovascular Physiology; 22: 253-258, 1993)</td>
<td>Other cardiovascular condition, Double-blind, Active-controlled, Parallel groups</td>
<td>Nebivolol 5 mg: 15/? Atenolol 50 mg: 15/?</td>
</tr>
<tr>
<td>125</td>
<td>109097</td>
<td>FRA-7</td>
<td>Comparative Study of Intravenous Nebivolol, Propranolol and Labetalol in Obese Subject: Part I- Hemodynamics. Synoptic Clinical Research Report NEB-FRA-7. November 1994.</td>
<td>Other cardiovascular condition, Double-blind, Active-controlled, Cross-over</td>
<td>Nebivolol 0.07mg/kg: 19/-6 Propanolol 0.1mg/kg: 19/-4 Labetalol 0.9mg/kg: 19/-8</td>
</tr>
<tr>
<td>128</td>
<td>82501</td>
<td>BEL-33</td>
<td>The Effect of Nebivolol in Patients with Left Ventricular Diastolic Dysfunction. (Acta Antwerpensa; 1991).</td>
<td>Other cardiovascular condition, Open-label</td>
<td>Nebivolol 5 mg: 12/?</td>
</tr>
<tr>
<td>131</td>
<td>72317</td>
<td>GER-1</td>
<td>Hemodynamic Effects of Nebivolol at Rest and On Exertion in Patients with Heart Failure. (Angiology; 41: 696-701, 1990).</td>
<td>Other cardiovascular condition, Open-label</td>
<td>Nebivolol 5 mg: 10/?</td>
</tr>
</tbody>
</table>

[*Sample size/Mean change from baseline at endpoint intent-to-treat (supine DBP at trough mmHg). ?denotes data not available.]
<table>
<thead>
<tr>
<th>#</th>
<th>Study ID</th>
<th>Title</th>
<th>Sponsor/Design</th>
<th>Efficacy Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>132</td>
<td>NAP 01</td>
<td>Randomized, Multicenter, Multinational, Dose Ranging Placebo-Controlled Comparative Study of Nebivolol, 2.5, 5, 10 and 20 mg / day in Patients with Stable Angina Pectoris</td>
<td>Double-Blind, Placebo-Controlled, Parallel groups</td>
<td>Data not available</td>
</tr>
<tr>
<td>133</td>
<td>MR/01-99/01-Nhf</td>
<td>Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors with Heart Failure</td>
<td>Multi-Centre, Multi-National, Randomized, Parallel group, Placebo-Controlled, Double-Blinded Study, Phase III</td>
<td>Ongoing</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/ Type/Design</td>
</tr>
<tr>
<td>----</td>
<td>---------</td>
<td>----------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------</td>
</tr>
<tr>
<td>134</td>
<td>N/A</td>
<td>NEBI-0126</td>
<td>Single-Dose, Dose-Proportionality Pharmacokinetic Study of Nebivolol Hydrochloride in Healthy Volunteers Characterized According to Their Metabolizing Status</td>
<td>Pharmacokinetic, ADME Open-label</td>
</tr>
<tr>
<td>135</td>
<td>N/A</td>
<td>NEBI-0127</td>
<td>Single-Dose, Relative Bioavailability and Food Effect Study of Nebivolol Hydrochloride in Healthy Volunteers Characterized According to Their Metabolizing Status</td>
<td>Pharmacokinetic, ADME Open-label Single dose</td>
</tr>
</tbody>
</table>
| 136| N/A     | NEBI-0136| Absorption, Metabolism, and Excretion of Nebivolol in Healthy Male Volunteers after a Single Oral Dose of 15 mg ^14^C-Nebivolol HCL July 27, 2001 | Pharmacokinetic, ADME Open-label | 6 fasting healthy male subjects (3 EM and 3 PM) drank a 60 mL solution containing approximately 100 μCi/15 mg (free base equivalent) 14C-nebivolol HCL and 180 mL of water. Results:  
   a. No serious AEs.  
   b. Maximum radioactivity levels in blood plasma attained in 2 hours in EM and at 4 hours in PM  
   c. CPEAK values of total radioactivity in blood or plasma comparable between EM and PM, but systemic exposure values based on AUCL differed 2.6 fold between EM and PM.  
   d. The apparent terminal elimination half-lives of total radioactivity obtained from PM were longer in blood (73.1 hr) than that in plasma (60.1 hr).  
   e. Mean blood-to-plasma total radioactivity ratios of less than 1 were observed for both CPEAK and AUCL. |
<p>| 137| N/A     | NEBI-0142| Metabolism of[^14]C]-Nebivolol in Human: Mass Balance and Metabolite Profiling/Identification in | Pharmacokinetic, ADME Open-label | 6 male subjects (3 EMs and 3 PMs). Single oral dose of nebivolol 15 mg. Blood, urine, and feces collected up to either 14 days for EM subjects or 18 days for PM subjects. In general, 38.36% and 66.49% of administered |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>LMD No.</th>
<th>Study ID</th>
<th>Title</th>
<th>Study Category/ Type/Design</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Plasma and Excreta</td>
<td></td>
<td>beverage was recovered in urine and 43.57% and 13.06% of radioactivity was recovered in feces for EMs and PMs, respectively. Tmax was 2 hrs for EMs and 4 hrs for PMs. Major metabolic pathways include formation of glucuronides of unchanged drug, mono- to multiple-hydroxylations on alicyclic and/or aromatic rings followed by glucuronidation, and formation of N-dealkylated derivatives. Glucuronidation of d-nebivolol occurred much more rapidly than on the l-enantiomer. The ratio of d-nebivolol glucuronide/l-nebivolol glucuronide in urine was ca. 80:20. In plasma, most of the metabolites detected were glucuronides of unchanged drug in addition to oxidative N-dealkylated acid. Some oxidative hydroxylated conjugates were also detected in plasma of EM subjects, however, they were low in PM subjects. 19 metabolites identified in feces, plasma, and urine.</td>
</tr>
<tr>
<td>138</td>
<td>N/A</td>
<td>NEBI-0223</td>
<td>A Phase I Open-Label Single-Dose Study Assessing the Pharmacokinetics of Nebivolol HCL and the Formation of Metabolites in Healthy Volunteers</td>
<td>Pharmacokinetic, ADME Open-label</td>
<td>8 healthy nonsmoking males and females (4 EM and 4 PM), ages 22-38. Open-label, one period study. Single dose of nebivolol HCL 10 mg. All subjects completed the study. Results: Higher nebivolol plasma concentrations (7 hrs vs. 1 hr).and a longer half-life seen in PMs compared to EMs (57 hrs for PMs, 10 hrs for EMs). 5 fold difference in maximum plasma concentration of d,l nebivolol between EM and PM subjects. Large differences in AUC between EM and PM subjects were observed (EMs: 8.982, 2.836, and 6.082 vs. PMs 272.2, 95.94, and 176.2 ng*hr/mL for d,l-nebivolol, d-nebivolol, and l-nebivolol, respectively). Lab, vital sign, and ECG monitoring—no safety risk. No AEs reported.</td>
</tr>
<tr>
<td>#</td>
<td>LMD No.</td>
<td>Study ID</td>
<td>Title</td>
<td>Study Category/Type/Design</td>
<td>Results</td>
</tr>
<tr>
<td>---</td>
<td>---------</td>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
<td>----------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>139</td>
<td>N/A</td>
<td>NEBI-0270</td>
<td>A Phase I Open-Label Multiple-Dose Study Assessing the Pharmacokinetics of Nebivolol HCL in Healthy Volunteers</td>
<td>Pharmacokinetic, ADME</td>
<td>Open-label one period, multiple-dose study. 25 healthy adult, tobacco-free volunteers enrolled (17 EMs and 8 PMs). 22 subjects (16 EM and 6 PM) between the ages of 19 and 53 completed this study. Nebivolol 10 mg given on Day 1 post supervised overnight fast (at least 10 hours). Then, on Day 4, subjects received a single oral 10 mg nebivolol HCL tablet daily for 14 consecutive days. Results: 1. TPEAK for EM subjects 1.2 hours for d- nebivolol, l-nebivolol, and d,l-nebivolol, compared with 2.7 hours for nebivolol glucuronides. 2. Mean TPEAK for PM subjects was 3.8, 5.7, 3.7, and 3.7 hours for d, l, d,l-nebivolol, and nebivolol glucuronides. 3. PM subjects had an approximately 5, 11, 9, and 4-fold higher mean CPEAK for d, l, d,l-nebivolol, and nebivolol glucuronides, compared with EMs. 4. PMs had mean AUCTAU values 14-fold, 43-fold, 32-fold, and 6-fold greater than their EM counterparts. 5. Mean t1/2 for EMS: 13, 17, 13, and 7 hours for d, l, d,l-nebivolol, and glucuronides. 6. For PMs, mean t1/2: 22, 73, 56, and 33 hours for d, l, d,l-nebivolol, and glucuronides. 7. In EMs, nebivolol glucuronides statistically significant (p &lt; 0.05) for KEL. For PMs, AUCTAU, CPEAK and HALF values at steady-state displayed a statistically significant difference relative to a single-dose administration of nebivolol glucuronides. 7. PMs will experience a 3-fold increase in peak plasma levels relative to their single-dose values following achievement of steady-state conditions. For EMs, single-dose PK disposition is indicative of what their steady-state PK disposition will be. Subject 1 dropped out of study on Day 5 (9/11/2002) due to personal reasons that were not study related. Subject 16 dropped out of study on Day 12 due to an adverse experience (abdominal pain) that required hospitalization. Subject 23 dropped out on 11/2/2002 (Day 1) due to an adverse event (nausea).</td>
</tr>
</tbody>
</table>